

1 Mitochondrial genome copy number measured by DNA  
2 sequencing in human blood is strongly associated with  
3 metabolic traits via cell-type composition differences  
4

5 Liron Ganel,<sup>1,2</sup> Lei Chen,<sup>1,2</sup> Ryan Christ,<sup>1</sup> Jagadish Vangipurapu,<sup>3</sup> Erica Young,<sup>1,4</sup> Indrani Das,<sup>1</sup>  
6 Krishna Kanchi,<sup>1</sup> David Larson,<sup>1,5</sup> Allison Regier,<sup>1,2</sup> Haley Abel,<sup>1,2,5</sup> Chul Joo Kang,<sup>1</sup> Alexandra Scott,<sup>1,2</sup>  
7 Aki Havulinna,<sup>6,7</sup> Charleston W. K. Chiang,<sup>8,9</sup> Susan Service,<sup>10</sup> Nelson Freimer,<sup>10</sup> Aarno Palotie,<sup>6,11,12</sup>  
8 Samuli Ripatti,<sup>6,12,13</sup> Johanna Kuusisto,<sup>3,14</sup> Michael Boehnke,<sup>15</sup> Markku Laakso,<sup>3,14</sup> Adam Locke,<sup>1,2</sup>  
9 Nathan O. Stitzel,<sup>1,4,5\*</sup> Ira M. Hall,<sup>1,2,16\*</sup>  
10 <sup>1</sup> McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, United  
11 States of America  
12 <sup>2</sup> Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States of  
13 America  
14 <sup>3</sup> Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland  
15 <sup>4</sup> Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St.  
16 Louis, MO, United States of America  
17 <sup>5</sup> Department of Genetics, Washington University School of Medicine, St. Louis, MO, United States of  
18 America  
19 <sup>6</sup> Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland  
20 <sup>7</sup> Finnish Institute for Health and Welfare (THL), Helsinki, Finland  
21 <sup>8</sup> Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine,  
22 University of Southern California, Los Angeles, CA, United States of America  
23 <sup>9</sup> Quantitative and Computational Biology Section, Department of Biological Sciences, University of  
24 Southern California, Los Angeles, CA, United States of America  
25 <sup>10</sup> Center for Neurobehavioral Genetics, Jane and Terry Semel Institute for Neuroscience and Human  
26 Behavior, University of California Los Angeles, Los Angeles, CA, United States of America  
27 <sup>11</sup> Analytical and Translational Genetics Unit (ATGU), Psychiatric & Neurodevelopmental Genetics  
28 Unit, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United  
29 States of America  
30 <sup>12</sup> Broad Institute of MIT and Harvard, Cambridge, MA, United States of America  
31 <sup>13</sup> Faculty of Medicine, University of Helsinki, Helsinki, Finland  
32 <sup>14</sup> Department of Medicine, Kuopio University Hospital, Kuopio, Finland  
33 <sup>15</sup> Department of Biostatistics and Center for Statistical Genetics, University of Michigan School of  
34 Public Health, Ann Arbor, MI, United States of America  
35 <sup>16</sup> Department of Genetics, Yale University School of Medicine, New Haven, CT, United States of  
36 America  
37 \* Correspondence: [ira.hall@yale.edu](mailto:ira.hall@yale.edu) (I.M.H.), [nstitzel@wustl.edu](mailto:nstitzel@wustl.edu) (N.O.S.)

38

## 39 **Abstract**

40 Mitochondrial genome copy number (MT-CN) varies among humans and across tissues and is highly  
41 heritable, but its causes and consequences are not well understood. When measured by bulk DNA  
42 sequencing in blood, MT-CN may reflect a combination of the number of mitochondria per cell and  
43 cell type composition. Here, we studied MT-CN variation in blood-derived DNA from 19,184 Finnish  
44 individuals using a combination of genome (N = 4,163) and exome sequencing (N = 19,034) data as  
45 well as imputed genotypes (N = 17,718). We identified two loci significantly associated with MT-CN  
46 variation: a common variant at the *MYB-HBS1L* locus ( $P = 1.6 \times 10^{-8}$ ), which has previously been  
47 associated with numerous hematological parameters; and a burden of rare variants in the *TMBIM1*  
48 gene ( $P = 3.0 \times 10^{-8}$ ), which has been reported to protect against non-alcoholic fatty liver disease. We  
49 also found that MT-CN is strongly associated with insulin levels ( $P = 2.0 \times 10^{-21}$ ) and other metabolic  
50 syndrome (metS) related traits. Using a Mendelian randomization framework, we show evidence that  
51 MT-CN measured in blood is causally related to insulin levels. We then applied an MT-CN polygenic  
52 risk score (PRS) derived from Finnish data to the UK Biobank, where the association between the  
53 PRS and metS traits was replicated. Adjusting for cell counts largely eliminated these signals,  
54 suggesting that MT-CN affects metS via cell type composition. These results suggest that  
55 measurements of MT-CN in blood-derived DNA partially reflect differences in cell-type composition  
56 and that these differences are causally linked to insulin and related traits.

57

## 58 **Introduction**

59 There are many reported links between mitochondrial content and cardiometabolic phenotypes in  
60 various tissues, including adipose<sup>1–3</sup>, liver<sup>1,4,5</sup>, skeletal muscle<sup>1,6–10</sup>, and blood<sup>11–17</sup>. Traits associated

61 with mitochondrial (MT) content include coronary heart disease (CHD), type 2 diabetes, and  
62 metabolic syndrome traits such as insulin sensitivity/resistance, obesity, and blood triglycerides.  
63 However, these studies have generally been limited by small sample sizes and low statistical power.  
64 This, in addition to the use of heterogeneous mitochondrial quantification methods<sup>18</sup>, has led to  
65 inconsistencies in the literature about the strength and directions of effect between mitochondrial  
66 content and metabolic syndrome (metS) traits. In one large WGS study of mitochondrial genome copy  
67 number (MT-CN) in 2,077 Sardinians, Ding *et al.* estimated the heritability of MT-CN at 54% and  
68 detected significant associations between MT-CN and both waist circumference and waist-hip ratio,  
69 but found no association with body mass index (BMI)<sup>11</sup>. Another large study (N = 5,150) found  
70 virtually no evidence of association between qPCR-measured MT-CN and any of several  
71 cardiometabolic phenotypes<sup>19</sup>. The only exception was an inverse association with insulin that was  
72 identified in one cohort but did not survive meta-analysis across cohorts. However, a study of 21,870  
73 individuals from 3 cohorts showed a significant inverse relationship between MT-CN (measured by  
74 microarray probe intensities in two cohorts and qPCR in the third) and incident cardiovascular  
75 disease<sup>20</sup>.

76         Although variations in MT-CN measured from whole blood can in principle be attributed to  
77 either variability of MT copy number within cells or the cell type composition of the blood (given that  
78 different cell types have varying MT content<sup>21-23</sup>), the literature on this subject is inconclusive. Using  
79 CpG methylation data, a large (N = 11,443), low-coverage (1.7x autosomal; 102x mitochondrial)  
80 sequencing study of the link between MT-CN and major depressive disorder using buccal DNA from  
81 Chinese women concluded that variability of MT-CN from buccal swabs was not due to differences in  
82 cell type composition<sup>24</sup>. However, this study did not do a similar experiment in blood. Two small (N =  
83 756 and N = 400) studies identified an association between MT content and CHD that they attributed  
84 to variable MT-CN within leukocytes, but they did not directly investigate the possibility of cell type

85 composition being the true driver of the association<sup>12,17</sup>. For brevity, we will use the term “MT-CN” to  
86 refer to the underlying phenotype reflected by measuring this quantity for the remainder of this work,  
87 with these caveats.

88 While several studies have found that peripheral blood MT content is heritable, only a small  
89 number of MT-CN associated loci have been identified<sup>25–27</sup>. In one of these studies, Curran *et al.* used  
90 linkage analysis in Mexican Americans to find an MT-CN associated locus near a marker previously  
91 associated with triglyceride levels<sup>26,28,29</sup>, providing further indirect evidence for the link between  
92 MT-CN and metabolic syndrome.

93 Here, we take advantage of large-scale genome, exome, and array genotype data to  
94 investigate the causes and effects of MT-CN in a large, deeply phenotyped Finnish cohort. Our  
95 results reveal novel links with metabolic syndrome and provide evidence supporting a causal role for  
96 MT-CN.

97

## 98 **Material and Methods**

### 99 **Genotype and phenotype data**

100 Whole genome sequencing (WGS) was performed on a cohort of 4,163 samples comprising 3,074  
101 male samples from the METSIM study<sup>30</sup> and 1,089 male and female samples from the FINRISK  
102 study<sup>31</sup>. Genomic DNA was fragmented on the Covaris LE220 instrument targeting 375 bp inserts.  
103 Automated Illumina libraries were constructed with the TruSeq PCR-free (Illumina) or KAPA Hyper  
104 PCR-free library prep kit (KAPA Biosystems/Roche) on the SciClone NGS platform (Perkin Elmer).  
105 The fragmented genomic DNA was size-selected on the SciClone instrument with AMPure XP beads  
106 to tighten the distribution of fragmented DNA to ensure the average insert of the libraries was  
107 350-375 bp. We followed the manufacturer’s protocol as provided by Perkin Elmer, with the following  
108 exception: post ligation, the libraries were purified twice with a 0.7x AMPure bead/sample ratio to

109 eliminate any residual adaptors present. An aliquot of the final libraries was diluted 1:20 and  
110 quantitated on the Caliper GX instrument (Perkin Elmer). The concentration of each library was  
111 accurately determined through qPCR utilizing the KAPA library Quantification Kit according to the  
112 manufacturer's protocol (KAPA Biosystems/Roche) to produce cluster counts appropriate for the  
113 Illumina HiSeqX instrument. Libraries were pooled and run over a few lanes of the HiSeq X to ensure  
114 the libraries within the pool were equally balanced. The final pool of balanced libraries was loaded  
115 over the remaining number of HiSeq X lanes to achieve the desired coverage for this project. 2x150  
116 paired end sequence data were demultiplexed using a single index, which was a restriction on the  
117 HiSeqX instrument at this time. A minimum of 19.5x coverage was achieved per sample.

118 The quality of the aligned sequence data was assessed using metrics generated by Picard<sup>32</sup>  
119 v2.4.1, Samtools<sup>33</sup> v1.3.1 and VerifyBamID<sup>34</sup> v1.1.3. Based on the output files from Picard, the  
120 following alignment statistics were collected for review: PF\_MISMATCH\_RATE, PF\_READS,  
121 PF\_ALIGNED\_BASES, PCT\_ADAPTER, PCT\_CHIMERAS, PCT\_PF\_READS\_ALIGNED,  
122 PCT\_READS\_ALIGNED\_IN\_PAIRS, PF\_HQ\_ALIGNED\_BASES, PF\_HQ\_ALIGNED\_Q20\_BASES,  
123 PF\_HQ\_ALIGNED\_READS, MEAN\_INSERT\_SIZE, STANDARD\_DEVIATION,  
124 MEDIAN\_INSERT\_SIZE, TOTAL\_READS, PCT\_10x, and PCT\_20x. Alignment rate was calculated  
125 as PF\_READS\_ALIGNED/TOTAL\_READS. The formula for haploid coverage was as follows:

126  $Haploid\ coverage = MEAN\_COVERAGE * \frac{1 - PCT\_EXC\_DUPE}{1 - PCT\_EXC\_TOTAL}$ . From the Samtools output,  
127 inter-chromosomal rate was calculated as:  $\frac{reads\_mapped\_in\_interchromosomal\_pairs}{reads\_mapped\_in\_pair}$  and discordant rate was  
128 calculated as:  $reads\_mapped\_percentage - reads\_mapped\_in\_proper\_pairs\_percentage$ .

129 Properly paired percentage ( $reads\_mapped\_in\_proper\_pairs\_percentage$ ) and singleton percentage  
130 ( $reads\_mapped\_as\_singleton\_percentage$ ) were also reviewed. From VerifyBamID, the Freemix  
131 value was reviewed.

132 The metrics for judgement of passing data quality were: FIRST\_OF\_PAIR\_MISMATCH\_RATE  
133  $< .05$ , SECOND\_OF\_PAIR\_MISMATCH\_RATE  $< 0.05$ , haploid coverage  $\geq 19.5$ , interchromosomal  
134 rate  $< .05$ , and discordant rate  $< 5$ . All of the above metrics must have been met in order for the  
135 sample to be assigned as QC pass. If a sample did not meet the passing criteria, the following failure  
136 analysis was performed: a) If the Freemix score was at least 0.05, the sample or the library was  
137 considered contaminated, and both the library and the sample were abandoned; b) if the discordant  
138 rate was over 5 and/or the inter-chromosomal rate was over 0.05, the quality of DNA was considered  
139 poor and the sample was removed from the sequencing pipeline; and c) in the case of a) and b), the  
140 collaborator was contacted to determine if selection of a replacement sample from the same cohort  
141 was desired or feasible.

142 Separately, whole exome sequencing (WES) data (N = 19,034), genotyping array data (N =  
143 17,718) imputed using the Haplotype Reference Consortium panel<sup>35</sup> v1.1, and transformed,  
144 normalized quantitative cardiometabolic trait data were obtained from an earlier study<sup>36</sup>. FINRISK  
145 array data came in nine genotyping batches, two of which were excluded from the present study due  
146 to small sample size. The traits, normalization and transformation procedures, and sample sizes are  
147 described in a previous publication<sup>36</sup>. The WES and imputed sample sets contained 4,013 and 3,929  
148 of the 4,163 WGS samples included in the present study.

149 All participants in both the METSIM and FINRISK studies provided informed consent, and  
150 study protocols were approved by the Ethics Committees at participating institutions (National Public  
151 Health Institute of Finland; Hospital District of Helsinki and Uusimaa; Hospital District of Northern  
152 Savo). All relevant ethics committees approved this study.

153

154 **WGS callset generation and quality control**

155 Single nucleotide polymorphisms (SNPs) and small insertions and deletions were called from the full  
156 set of 4,163 samples using GATK<sup>37</sup> v3.5. GVCFs containing SNVs and Indels from GATK  
157 HaplotypeCaller (-ERC GVCF -QQB 5 -QQB 20 -QQB 60 -variant\_index\_type LINEAR  
158 -variant\_index\_parameter 128000) were first processed to ensure no GVCF blocks crossed  
159 boundaries every 1 Mb (CombineGVCFs; --breakBandsAtMultiplesOf 1000000). The  
160 resulting GVCFs were then processed in 10 Mb shards across each chromosome. Each shard was  
161 combined (CombineGVCFs), genotyped (GenotypeGVCFs; -stand\_call\_conf 30  
162 -stand\_emit\_conf 0), hard filtered to remove alternate alleles uncalled in any individual removed  
163 (SelectVariants; --removeUnusedAlternates), and hard filtered to remove lines solely reporting  
164 symbolic deletions in parallel. All shards were jointly recalibrated (VariantRecalibrator) and then  
165 individually filtered (ApplyRecalibration) based on the recalibration results. All of the above methods  
166 were performed using GATK v3.5. SNP variant recalibration was performed using the following  
167 options to VariantRecalibrator and all resources were drawn from the GATK hg38 resource bundle  
168 (v0):

```
169     -mode SNP
170     -resource:hapmap,known=false,training=true,truth=true,prior=15.0
171     -resource:omni,known=false,training=true,truth=true,prior=12.0
172     -resource:1000G,known=false,training=true,truth=false,prior=10.0
173     -resource:dbsnp,known=true,training=false,truth=false,prior=2.0
174     -an QD -an DP -an FS -an MQRankSum -an ReadPosRankSum
175     -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0
```

176 Indel variant recalibration was performed using the following options to VariantRecalibrator (with the  
177 same resource bundle as with SNPs):

```
178     -mode INDEL
```

```
179 -resource:mills,known=true,training=true,truth=true,prior=12.0
180 -an DP -an FS -an MQRankSum -an ReadPosRankSum
181 --maxGaussians 4
182 -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0
```

183 When applying the variant recalibration the following options were used:

184 For SNPs: `--ts_filter_level 99.0`

185 For Indels: `--ts_filter_level 99.0`

186

187 Following SNP and INDEL variant recalibration, multiallelic variants were decomposed and  
188 normalized with vt<sup>38</sup> v0.5. Duplicate variants and variants with symbolic alleles were subsequently  
189 removed. The bottom tranche of variants identified by GATK's Variant Quality Score Recalibration tool  
190 and variants with missingness greater than 2% were removed as well, although variants with allele  
191 balance between 0.3 and 0.7 were rescued. Variants with Hardy-Weinberg equilibrium (on a  
192 second-degree unrelated subset of 3,969 individuals, as determined by KING<sup>39</sup>) P value less than  $10^{-6}$   
193 and those with allele balance less than 0.3 or greater than 0.7 were also removed.

194 Sample-level quality control was also undertaken on this dataset; 13 samples were identified  
195 for exclusion because of singleton counts that were at least eight median absolute deviations above  
196 the median. Separately, 12 sex-discordant samples were flagged using `plink --check-sex`, and  
197 after examining chromosome Y missingness and F coefficient values for these samples, only the one  
198 that clearly differed from its reported sex was marked for exclusion. No samples were excluded based  
199 on missingness fraction or the first five principal components. In total, 14 samples were excluded from  
200 the heritability, GWAS, and Mendelian randomization analyses; the other analyses were performed  
201 without exclusion of these samples. As a result, the former analyses were performed with  $N = 4,149$   
202 while the latter had  $N = 4,163$ .



203

## 204 Mitochondrial genome copy number estimation

205 We estimated mitochondrial genome copy number (MT-CN) from both WGS and WES data. In WGS  
206 data, we used BEDTools<sup>40</sup> to calculate per-base coverage on the mitochondrial genome from the  
207 latest available 4,163 WGS CRAM files. MT-CN was then calculated by normalizing the mean  
208 coverage of the mitochondrial genome to the "haploid coverage" of the autosomes as calculated by  
209 Picard<sup>32</sup>. The result was then doubled to account for the diploidy of the autosomal genome. This  
210 normalization is summarized by the following equation:  $MT\_CN_{WGS} = 2 \times \frac{\text{mean mtDNA coverage}}{\text{haploid autosomal coverage}}$ .

211 The output from the above equation served as the raw measurement of per sample MT-CN. To  
212 reduce batch effects, we separated the 4,163 samples into three groups: METSIM, FINRISK collected  
213 in 1992 or 1997, and FINRISK collected in 2002 or 2007 (the FINRISK batching decisions were made  
214 based on the means shown in **Figure S4**). Within each cohort, the raw estimates were regressed on  
215 age, age<sup>2</sup> and sex (FINRISK only) and the residuals were inverse-normal transformed. We combined  
216 the three batches of normalized MT-CN values and inverse-normal transformed the combined values  
217 for downstream analysis.

218 We used a similar procedure to estimate MT-CN from WES data, with mean autosomal  
219 coverage estimates taken from XHMM<sup>41</sup>. However, as mitochondrial genomic coverage was  
220 nonuniform due to the use of hybrid capture probes, mean mtDNA coverage was not an obvious  
221 choice of metric for MT-CN estimation (**Figure S5**). To summarize this nonuniform mitochondrial  
222 genomic coverage into a single number, we tried taking the mean and the maximum depth of reads  
223 that aligned to the mitochondrial chromosome; the resulting values were then processed in the same  
224 way as the WGS-estimated values. We evaluated the approaches by measuring the R<sup>2</sup> between  
225 WGS-estimated and WES-estimated MT-CN in the 4,013 samples for which both data types were  
226 available (**Figure S6**). While R<sup>2</sup> was fairly high using both approaches, the maximum coverage

227 method was ultimately selected for use as it yielded a higher  $R^2$  (0.445 vs 0.380). As a result, the

228 WES MT-CN estimate was calculated as follows:  $MT\_CN_{WES} = 2 \times \frac{\text{maximum mtDNA coverage}}{\text{mean haploid autosomal coverage}}$ .

229

### 230 **Mitochondrial haplogroup estimation**

231 We assigned mitochondrial haplogroups using HaploGrep<sup>42</sup> v1.0. Mitochondrial SNP/indel variants  
232 were genotyped using GATK GenotypeGVCFs, and a customized filter based on allele balance was  
233 applied to the combined callset. HaploGrep was then used to call mitochondrial haplotypes for each  
234 individual. We adjusted for major haplogroups in the same linear regressions of metabolic traits onto  
235 MT-CN (see Results) and calculated the summary statistics from a permutation test as implemented  
236 in the R package ImPerm.

237

### 238 **Heritability analysis**

239 To estimate heritability of MT-CN, a genomic relatedness-based restricted maximum-likelihood  
240 (GREML) method was used as implemented in GCTA<sup>43</sup>. The original GREML<sup>44</sup> method was used first,  
241 followed by GREML-LDMS<sup>45</sup> to account for biases arising from differences in minor allele frequency  
242 (MAF) spectrum or linkage disequilibrium (LD) properties between the genotyped variants and the  
243 true causal variants<sup>46</sup>. For both analyses, MT-CN values were normalized and residualized for sex,  
244 age, and age<sup>2</sup> as described above. Heritability estimation was performed jointly and separately for  
245 METSIM and FINRISK samples using WGS and imputed array genotypes. In all cases, a minimum  
246 MAF threshold of 1% was applied. Beyond those covariates already adjusted for in the normalization  
247 process, sensitivity analyses were performed on imputed array data to determine whether heritability  
248 estimates were sensitive to inclusion of covariates. In these experiments, either cohort or FINRISK  
249 genotyping array batch were included as fixed-effect covariates in joint analyses of imputed array  
250 data; in neither case was the final heritability estimate significantly affected ( $h^2 = 0.09$ , SE = 0.02 in

251 both cases). In GREML-LDMS, genotypes were split into four SNP-based LD score quartiles and two  
252 MAF bins ( $1\% > \text{MAF} > 5\%$  and  $\text{MAF} > 5\%$ ), and genetic relatedness matrices (GRMs) were  
253 estimated separately for each of the eight combinations. The GREML algorithm was then run on all  
254 eight GRMs simultaneously using the first ten principal components (PCs) of the genotype matrix (as  
255 calculated by smartPCA v13050) as fixed covariates<sup>45</sup>. The use of GREML-LDMS over GREML also  
256 did not affect estimated heritability values (**Table 3**), suggesting that the properties of the causal  
257 variants for this trait do not lead to significant biases when using the standard GREML approach.

258 We observed that WGS heritability estimates decrease when analyzing FINRISK and METSIM  
259 data together compared to analysis of METSIM alone (**Table 2**) (note that FINRISK-only heritability  
260 estimates are not reliable as they have large standard errors resulting from the small number of  
261 FINRISK samples sequenced). One potential explanation for this is that there exists substantial  
262 heterogeneity across FINRISK survey years (**Figure S4**), and between the FINRISK and METSIM  
263 cohorts, with respect to the reliability with which mtDNA was captured (likely due to different DNA  
264 preparation protocols).

265

## 266 **Genome-wide association analyses**

267 Genome-wide association studies (GWAS) were performed using the same normalized phenotype  
268 used in heritability analyses. Single-variant GWAS were conducted using EMMAX as implemented in  
269 EPACTS. Kinship matrices required by EMMAX were generated by EPACTS; kinship matrices for  
270 WGS GWAS were generated from WGS data, while those for WES and imputed array based GWAS  
271 were generated from WES data. A P value threshold of  $5 \times 10^{-8}$  was used for the WGS and imputed  
272 array GWAS while  $5 \times 10^{-7}$  was used for significance in the WES GWAS. Single-variant association  
273 analyses of WGS and WES data did not include any covariates in the EMMAX model, although all  
274 association analyses were performed using MT-CN values that adjusted for age, age<sup>2</sup>, sex, and

275 cohort (see “Mitochondrial Genome Copy Number Estimation”). All association tests labeled “joint”  
276 were performed on METSIM and FINRISK cohorts together; in one case, a random-effects  
277 meta-analysis was performed using individual-cohort summary statistics and the R package meta<sup>47</sup>.

278 Gene-based variant aggregation studies (RVAS) were done using a mixed-model version of  
279 SKAT-O<sup>48</sup> as implemented in EFACTS. Variants with CADD<sup>49</sup> score greater than 20 and minor allele  
280 frequency less than 1% were grouped into genes as annotated by VEP<sup>50</sup> (which annotates a variant  
281 with a gene name if the gene falls within 5k of that gene by default). For gene-based RVAS,  
282 genome-wide significance thresholds varied slightly due to differing the number of genes with at least  
283 two variants meeting the above criteria in each test, but were approximately  $2 \times 10^{-6}$  in all cases.

284

## 285 **Mendelian randomization**

286 To assess the evidence for a causal relationship between mitochondrial genome copy number and  
287 fasting serum insulin levels, the METSIM cohort alone was used due to its homogeneity of sex,  
288 collection procedures, and location. A penalized regression based, multiple variant Mendelian  
289 randomization (MR) approach was employed to enforce the necessary assumptions of MR methods.  
290 While some MR studies have tested one or more assumptions *post hoc*, to our knowledge, there is no  
291 published method that tries to enforce these assumptions during the process of building the genetic  
292 instrument in the absence of a large set of known genotype-exposure associations. In our formulation  
293 (**Figure 4a**),  $X$ , the natural log of MT-CN (adjusted for nuclear genomic coverage but not for age,  
294 age<sup>2</sup>, or sex), and a genotype matrix  $G$  were used to build a genetic instrument  $Z$ , which was then  
295 tested against  $Y$ , the natural log of fasting serum insulin. The goal of the MR approach was to use a  
296 large number of common variants to build a genetic instrument  $Z$  that satisfied the three assumptions  
297 of MR<sup>51</sup>:

298 1. Association of  $Z$  with  $X$

299 2. Independence of Z from any variables U confounding the relationship between X and Y

300 3. Independence of Z and Y given X and U

301 To attempt to build a genetic instrument satisfying assumptions 2 and 3, the deep METSIM  
302 phenotype data were leveraged. A matrix  $W$  was constructed using the 75 measured traits and first  
303 20 PCs of the genotype matrix (including a third-degree polynomial basis for PC 1). From these  
304 variables, covariates that could violate one of these two assumptions were chosen by selecting  
305 columns of  $W$  associated with X or Y (**Figure 4b**). These columns were selected using two successive  
306 LASSO feature selection procedures. First, a set A of covariates associated with Y was chosen by  
307 using LASSO to regress Y onto  $W$ . In this regression, age and the third-degree polynomial basis for  
308 PC 1 were left unpenalized to ensure that A contains these covariates. The shrinkage parameter was  
309 chosen by tenfold cross-validation as the largest value that gives a mean squared error (MSE) within  
310 one standard error of the minimum observed MSE. Next, the columns of  $W$  associated with X  
311 conditional on A were chosen using a similar LASSO procedure in the regression of X onto  $W$ . In this  
312 step, however, the variables in set A were left unpenalized in order to only capture associations that  
313 are conditionally independent of A. The selected variables from this regression were designated set  
314 B.

315 The instrument was built using a penalized regression (using either an L1 or L2 penalty, as  
316 implemented in glmnet<sup>52</sup>) of the form  $X \sim G + W_A + W_B$ , where  $W_A$  and  $W_B$  are the columns of  $W$   
317 representing sets A and B, respectively, and  $G$  is a genotype matrix containing the alternate allele  
318 dosage (missing alleles are replaced with the MAF, similarly to PLINK<sup>53</sup>) of all variants with MAF  
319 greater than 1% and marginal GWAS P value below 0.01. As  $X$  was the target vector for this  
320 regression, assumption 1 of MR was trivial. In the penalized regression,  $W_A$  and  $W_B$  were unpenalized  
321 in an effort to orthogonalize the regression coefficients of the genotypes to these covariates in an  
322 effort to enforce assumptions 2 and 3. glmnet was run with a convergence threshold of  $1 \times 10^{-10}$  and

323 maximum number of iterations of 200,000. To avoid the overfitting that would result from calculating  
324 instrument values on the same samples on which regression coefficients are learned<sup>54</sup>, the penalized  
325 regression model was fit on independent subsets of the data as follows. Five models were fit, each by  
326 holding out a different 20% of samples, such that the instrument value computed for each sample  
327 was calculated using the regression coefficient vector learned without that sample. The vector of  
328 possible shrinkage parameters  $\lambda$  for all five models was supplied as  $(10^3, 10^2, \dots, 10^{-13}, 10^{-14})$ , and the  $\lambda$   
329 value which minimized the joint residual sum of squares of all five models was chosen for instrument  
330 calculation.

331 Formally, we randomly partitioned the set of samples  $S$  with nonmissing insulin measurements  
332 into five nonoverlapping sets  $S_j$  for  $j = \{1, \dots, 5\}$ . We denote set complements as  $S_j^C = S \setminus S_j$ , such  
333 that each  $S_j^C$  contained 80% of the training samples. The instrument vector  $Z_j$  for each  $S_j$  was  
334 computed as follows:  $Z_j = G_j \times \beta_G^{(-j)}$ , where  $Z_j$  is the instrument vector for  $S_j$ ,  $G_j$  is the genotype matrix  
335 of  $S_j$ , and  $\beta_G^{(-j)}$  is the vector of genotype regression coefficients from the model described above,  
336 trained on  $S_j^C$ . The instrument values within each  $S_j$  were inverse rank-normalized using a Blom  
337 transformation<sup>55,56</sup> before being concatenated across the values of  $j$  to give the final instrument vector  
338  $Z$ . Because samples with missing insulin values could not be included in the causality test anyway,  
339 these samples were excluded from  $S$  but safely included in the training sets of all five models. The  
340 instrument values of these samples were never calculated or used in downstream analyses.

341 Often, the inclusion of unpenalized covariate sets  $A$  and  $B$  in the instrument-building regression  
342 was not sufficient to completely orthogonalize  $Z$  to these covariates (see below). As a result, the test  
343 for association between  $Z$  and  $Y$  was performed conditional on a set of potentially  
344 assumption-violating covariates chosen using the newly constructed instrument  $Z$  in another attempt  
345 to account for possible violations of MR assumptions in the causality test (**Figure 4c**). To choose this  
346 set of covariates  $C$ , a final feature selection step was performed using LASSO regression of  $Z$  on  $W$

347 with covariate set  $A$  excluded from the penalty. As in the previous feature selection steps, the  
348 shrinkage parameter was chosen via tenfold cross-validation as the largest value with MSE within  
349 one standard error of the minimum observed MSE. Once this set,  $D$ , of covariates associated with  $Z$   
350 was chosen, the covariates in  $W$  were partitioned into sets I, II, III, and IV based on their membership  
351 in  $A$  and  $D$  (see **Figure 4**). Formally, this partitioning was done as follows:  $I = W \setminus (A \cup D)$ ,  
352  $II = D \cap A^C$ ,  $III = A \cap D^C$ , and  $IV = A \cap D$ , where  $A^C = W \setminus A$  and  $D^C = W \setminus D$ . Then, the test for  
353 causality came from the regression coefficient of  $Z$  in the multiple regression  $Y \sim Z + C$ , where  $C$  is  
354 the union of sets II, III, and IV (colored blue in **Figure 4c**).

355 To account for missing data in  $W$ , missing values were multiply imputed using regression trees  
356 as implemented in the R package `mice`<sup>57</sup> v3.4.0 (`maxit=25`). This imputation was repeated 1000  
357 times in parallel, with each set of imputed values being carried through the entire procedure  
358 described above. The resulting 1000 computed instrument effect sizes and standard errors were  
359 combined using Rubin's method as implemented in the R package `Amelia`<sup>58</sup> v1.7.5. The combined  
360 effect size and standard error were then tested for significance using a t-test with 998 degrees of  
361 freedom.

362 The above procedure was performed separately for METSIM samples with WGS data ( $N =$   
363 3,034) and METSIM samples with only imputed array data ( $N = 6,774$ ) using an L1 penalty in the  
364 instrument-building regression, and again using an L2 penalty. Both sample sets were limited to those  
365 for which relevant quantitative traits were available. An inverse-variance weighted meta-analysis was  
366 performed across data sets for L1 and L2-penalized regression separately. The resulting effect size  
367 and standard error were tested for significance using a Z test.

368 To ensure that our results were not driven by outlier samples, we removed outliers in two  
369 stages. Before the MR analyses, we used principal components analysis (PCA), Mahalanobis  
370 distance, and multi-trait extreme outlier identification to remove 5 WGS samples and 15 imputed

371 array samples based on quantitative trait data. We also removed high leverage, high residual outliers  
372 from the causality test regression (see below) *post hoc* and recomputed the instrument effect sizes to  
373 ensure that there was no significant change in the results. In each of the 1,000 multiple imputation  
374 runs, among the samples with standardized residual greater than 1, the top 10 samples by leverage  
375 were recorded. Any sample that was recorded in this way in at least one run was then excluded from  
376 the re-analysis as a *post hoc* outlier. The results of this additional analysis showed only very small  
377 differences in effect estimates, and their interpretation remained the same (**Table S9**). Thus, we  
378 concluded that our causal inference results were not driven by outlier samples.

379 One caveat of this method is that, as mentioned above, exclusion of sets A and B from the  
380 regression penalty did not perfectly orthogonalize the resulting instrument from these variables in  
381 practice (**Figure S7**). Reasons for this may include relatively low levels of shrinkage in the  
382 instrument-building regression or higher order associations between MT-CN and the confounding  
383 variables. However, our method still represents an improvement over the current standard, which is  
384 not to adjust for these covariates at all. Another caveat is that it is impossible to determine the perfect  
385 set of covariates for which adjustment is appropriate. Lack of adjustment for truly confounding  
386 variables can result in an instrument which does not satisfy MR assumptions 2 and/or 3, yielding a  
387 biased effect estimate. Conversely, unnecessary adjustment for certain variables can also result in  
388 biases. For example, adjusting for an intermediate phenotype that truly lies along the path from Z to X  
389 to Y can cause a false negative signal, making the causality test overly conservative. Alternatively,  
390 adjusting for some variables can result in collider biases<sup>59</sup>. That is, if both Z and Y are causal for a  
391 confounder U, then adjusting for U can induce a dependency between Z and Y (**Figure S8**) that did  
392 not previously exist.

393 We note that a known source of bias in MR studies is the selection of samples based on  
394 case-control status for a related disease<sup>60</sup>. While METSIM is a population-based study, samples were



395 selected for WGS based on cardiovascular disease case-control status so as to enrich the sequenced  
396 samples for cases. This has the potential to bias a MR experiment if both the exposure and the  
397 outcome are associated with the disease, which is certainly possible. However, in our design, all of  
398 the METSIM samples not chosen for WGS were tested in the imputed array experiment. The  
399 consistency of effect estimates between the WGS and imputed array samples both in the L1 and L2  
400 penalty cases (**Figure 4d**) suggests that there is little to no bias arising from sample selection in this  
401 experiment.

402

### 403 **Calculation and testing of polygenic risk score in the UK Biobank**

404 To search for associations between MT-CN and other phenotypes, the genetic instrument calculated  
405 in Finnish imputed array data was computed and treated as a polygenic risk score (PRS) in a  
406 relatively homogenous subset of 357,656 UK Biobank samples identified by a previous study<sup>61</sup>. We  
407 calculated  $\overline{\beta}_G$ , the average of the five values of  $\beta_G^{(i)}$  across all 1000 multiple imputation runs using an  
408 L2 penalty and imputed array data – the L2 penalty was chosen because it performed better than the  
409 L1 on both METSIM data types, and the imputed array data set was chosen due to its larger sample  
410 size than the WGS set (**Figure 4d**). Next, to keep the procedure as consistent as possible with the  
411 imputation protocol used for METSIM – which used haploid dosage values to call imputed  
412 genotypes<sup>36</sup> – we called imputed genotypes using the expected alternate allele dosage from the UK  
413 Biobank by setting thresholds of 0.5 and 1.5. Using the resulting imputed variant calls, we calculated  
414 our PRS as  $\tilde{Z} = \overline{\beta}_G \times \tilde{G}$ , where  $\tilde{G}$  is the UK Biobank genotype dosage matrix constructed in the  
415 same way as  $G$  in METSIM.

416 To test for associations with MT-CN PRS in the UK Biobank, we employed two approaches: a  
417 hypothesis-driven analysis targeted to the phenotypes associated with MT-CN in the Finnish data as  
418 well as a hypothesis-free screen of all the phenotypes available to us.

419 In the targeted analysis, we used our genetic instrument from the MR experiment as a PRS for  
420 MT-CN in our chosen subset of the UK Biobank and tested for associations with several blood cell  
421 count and metabolic syndrome traits. Given the association of MT-CN with rs9389268 (see Results),  
422 we selected as cell count traits total leukocyte count as well as lymphocyte, neutrophil, monocyte,  
423 and platelet counts for testing (because lymphocyte count was not readily available, it was calculated  
424 as the product of leukocyte count and lymphocyte percentage). We did not include basophils and  
425 eosinophils in this analysis considering that they comprise a small minority of white blood cells and  
426 are unlikely to affect MT-CN measured from whole blood. All cell count traits were log-transformed  
427 and standardized separately by sex.

428 We took several steps to eliminate outlier samples in the dataset. Through three iterations of  
429 PCA on the cell count matrix and subsequent outlier removal, we removed 1,637 outlier samples. We  
430 then fit null linear models of the form  $cell\ count \sim age + age^2 + sex + age : sex + age^2 : sex + PCs$  (the first  
431 20 PCs were included) for each cell count trait and subsequently removed samples with either large  
432 residuals or high leverage and moderate residuals in at least one model (following the example of <sup>61</sup>).  
433 Through two iterations of null model fitting and outlier removal, we removed 7 additional samples  
434 based on null model fit. Tests of association between cell counts and MT-CN PRS were based on the  
435 PRS regression coefficient in linear models of the form  
436  $cell\ count \sim PRS + age + age^2 + sex + age : sex + age^2 : sex + PCs$ .

437 We repeated this process for those cardiometabolic traits found to be suggestively associated  
438 with MT-CN in the Finnish dataset ( $P < 10^{-6}$ ) that were also readily available in the UK Biobank  
439 (**Figure 1a, Table S1**); these phenotypes were body mass index (BMI), fat mass, C-reactive protein,  
440 high-density lipoprotein, total triglycerides, and weight. We also chose to include T2D status because  
441 of the lack of insulin measurement in the UK Biobank. Except for T2D, a binary trait, all traits were  
442 log-transformed before further analysis (after removing 817 samples with negative values for T2D,

443 representing missing information). The above outlier removal steps were repeated for the  
444 cardiometabolic traits after excluding the outliers already identified from the cell count data, with the  
445 only major modification being the use of logistic regression for the T2D models. This process resulted  
446 in the removal of 42 and 53 samples from PCA and null model fitting, respectively.

447 SKAT-O tests of association between *TMBIM1* and the cell count traits identified above were  
448 also performed. Similarly to the RVAS in Finnish data, variants within 5kb of *TMBIM1* with MAF < 1%  
449 and CADD v1.6 score > 20 were selected for inclusion in this analysis. Rather than the mixed-model  
450 version of SKAT-O used in the Finnish data, standard SKAT-O was used due to the lower expected  
451 level of cryptic relatedness in the UK Biobank population.

452 We also performed a hypothesis-free, phenome-wide screen of UK Biobank traits to which we  
453 had access (**Table S10**), to search for other associations with MT-CN PRS. The statistical models  
454 used in this screen were of the same form as those described above, both with and without  
455 adjustment for neutrophil and platelet counts. To curate and transform phenotypes, we used an  
456 adapted version of PHESANT<sup>61,62</sup>. A few further modifications were made to the pipeline, the most  
457 significant being the direct use of logistic regression for testing categorical unordered variables, the  
458 inclusion of cancer phenotypes, and the exclusion of sex-specific (or nearly sex-specific) categorical  
459 traits. The PHESANT pipeline we used<sup>61</sup> outputs continuous variables both in their raw form and after  
460 applying an inverse rank normal transformation. For the sake of being conservative and robust to  
461 outliers, we chose to interpret the results from the normalized continuous variables. To control false  
462 discovery rate, we performed a Benjamini-Hochberg procedure with Storey correction as  
463 implemented in the R package *qvalue*<sup>63</sup> v2.18.0 on the categorical and normalized continuous  
464 variables together. As a secondary analysis, this same correction was applied to the categorical and  
465 raw continuous variables together.

466

## 467 Results

### 468 Association of MT-CN with metabolic traits

469 We estimated MT-CN in 4,163 individuals from the METSIM and FINRISK studies based on deep  
470 (>20x coverage) WGS data. We did so by measuring the mean coverage depth of reads mapped to  
471 the mitochondrial genome in each sample, and normalizing it to the mean autosomal coverage (see  
472 Material and Methods). We performed batch normalization separately for METSIM and for two  
473 FINRISK batches separated by survey years (see Material and Methods). Each measurement was  
474 adjusted for age, age<sup>2</sup>, and sex, then inverse rank normalized separately before combining across  
475 batches. We tested the resulting MT-CN estimates for association with 137 quantitative traits that  
476 were collected and normalized according to the procedures described previously<sup>36</sup>. MT-CN was  
477 strongly associated with fat mass ( $P = 4.48 \times 10^{-16}$ ) and fasting serum insulin ( $P = 2.02 \times 10^{-21}$ ), as  
478 well as numerous additional quantitative traits, many related to metabolic syndrome (**Figure 1a**,  
479 **Table S1**). Notably, BMI was significantly associated with MT-CN, although Ding *et al.* did not find  
480 evidence of this association<sup>11</sup>. Since population structure was a potential confounder in this analysis  
481 considering the presence of mtDNA polymorphisms that might adversely affect short-read alignment,  
482 we included SNP-inferred mitochondrial haplogroup as a covariate and reran the tests (**Figure 1b**).  
483 The association signals retained significance even after this adjustment.

484 To understand the connection between MT-CN and more clinically relevant phenotypes, we  
485 tested our MT-CN estimate against Matsuda ISI and disposition index (**Table 1**), which measure  
486 insulin sensitivity and secretion, respectively, and were not included in the initial screen. MT-CN was  
487 strongly associated with both insulin phenotypes. Notably, the Matsuda ISI signals survived  
488 adjustment for fat mass percentage after excluding diabetic individuals, which indicates that the  
489 association of peripheral blood MT-CN with insulin sensitivity was independent of fat mass.

490 To test for this association signal in a larger cohort, we developed a method to estimate  
491 mitochondrial genome copy number using 19,034 samples with whole exome sequencing (WES) data  
492 from the METSIM and FINRISK studies that included most of the WGS samples<sup>36</sup> (see Material and  
493 Methods).  $R^2$  between WGS-based and WES-based estimates was 0.445 (**Figure S6**). Consistent  
494 with the WGS-based analysis, WES-estimated MT-CN was significantly associated with both fat mass  
495 and fasting serum insulin levels, even after removing the samples with WGS data, with identical  
496 directions of effect (**Table S2**).

497 Anecdotally, it is interesting to note that these MT association signals can also be detected  
498 using read-depth analysis of the nuclear genome (**Figure S1**; manuscript under review<sup>64</sup> - preprint  
499 doi: 10.1101/2020.12.13.422502), where reads derived from mtDNA align erroneously to several  
500 nuclear loci based on homology between the MT genome and ancient nuclear mitochondrial  
501 insertions. This result provides additional evidence for the reported trait associations using an  
502 independent MT-CN estimation method, and indicates that these homology-based signals need to be  
503 taken into account in future CNV association studies.

504

## 505 **Heritability analysis**

506 To assess the extent to which MT-CN is genetically determined, we estimated the heritability of  
507 mitochondrial genome copy number using GREML (**Table 2**). We explored two different approaches  
508 available: (1) analysis of the 4,149 samples with WGS data that passed quality control measures,  
509 where both nuclear genotypes and MT-CN are measured directly from the WGS data, and (2)  
510 analysis of the set of 17,718 samples with imputed genotype array data, where MT-CN is estimated  
511 from WES data. Of these, (1) benefited from more accurate measurement of genotype and  
512 phenotype, whereas (2) had noisier measurements but benefited from larger sample size. We

513 focused primarily on the METSIM cohort, both because of the homogeneity of this cohort (see  
514 Material and Methods) and because the number of FINRISK samples with WGS data was small.

515 In the WGS analysis, the GREML-estimated heritability of MT-CN in METSIM was 31% -  
516 somewhat less than the 54% value reported in the only prior large-scale study of peripheral blood  
517 MT-CN heritability, which was based on low-coverage WGS<sup>11</sup>. For comparison, we used this same  
518 approach to estimate heritability of LDL in METSIM WGS data, which yielded an estimate of 34% with  
519 a standard error of 7.9% (**Table 3**). This is broadly consistent with prior work<sup>65,66</sup>, including analysis of  
520 the same Finnish sample set using distinct methods<sup>36</sup> (20.2% heritability). These results show that  
521 mitochondrial genome copy number is a genetically determined trait with significant heritability,  
522 comparable to that of LDL and other quantitative cardiometabolic traits<sup>36</sup>.

523 The analysis of imputed METSIM genotypes using WES-estimated MT-CN yielded an  
524 estimated heritability of 11%, which is much lower than the WGS-based estimate (**Table 2**). To  
525 understand this discrepancy, we repeated the GREML analysis with the other two combinations of  
526 phenotype source (WGS vs. WES estimation) and genotype source (WGS vs. imputed array). When  
527 using the WGS-measured phenotype, the estimated heritability decreased only slightly (31% to 27%)  
528 when switching from the WGS to imputed genotypes. This suggests that the difference in genotyping  
529 method was not the main driver of the observed heritability disparity between the WGS and imputed  
530 array datasets. Conversely, when analyzing the imputed METSIM genotypes, switching from  
531 WGS-measured to WES-measured MT-CN resulted in a large drop (27% to 11%) in estimated  
532 heritability. This suggests that the extra noise inherent in WES-based MT-CN estimates was  
533 responsible for the reduction in the GREML-estimated heritability despite the increased sample size  
534 of the imputed array dataset.

535

536 **Identification of genetic factors associated with MT-CN**

537 Previous studies have identified three autosomal quantitative trait loci (QTL) reaching genome-wide  
538 significance for MT-CN in other populations<sup>25,26</sup>. Another recent study identified two putative QTLs  
539 with suggestive P values<sup>27</sup>. We conducted single variant GWAS for MT-CN (see Material and  
540 Methods). Analysis of WGS (N = 4,149) and WES (N = 19,034) genotypes yielded no variants  
541 exceeding the respective significance thresholds of  $5 \times 10^{-8}$  and  $5 \times 10^{-7}$  (**Figure S2**). However, despite  
542 the increased noise in the WES-measured phenotype, GWAS of imputed array genotypes from  
543 METSIM (N = 9,791) yielded two loci with genome-wide significant associations, identified by lead  
544 markers rs2288464 and rs9389268 (**Figure 2, Table 4**). Of the previously-reported MT-CN QTLs<sup>25-27</sup>,  
545 we observed an inconclusive signal at rs445 (P = 0.048) and a significant signal at rs709591 (P =  
546  $1.61 \times 10^{-4}$ ), a locus associated with neutrophil count<sup>67,68</sup> (**Table S11**). No significant signal was  
547 observed at the other two single-variant QTLs (**Table S11**) or the linkage peak identified by Curran *et*  
548 *al.* (**Figure S3**).

549 rs9389268 was the only marker that was strongly associated with MT-CN in the METSIM  
550 analyses of both WGS and imputed array data (P =  $3.24 \times 10^{-8}$  and P =  $1.26 \times 10^{-10}$ , respectively).  
551 Although this variant was not significantly associated with MT-CN in FINRISK (P = 0.788 and P =  
552 0.189 in WGS and imputed array data, respectively) or in a separate random-effects meta-analysis of  
553 both cohorts (P = 0.115), the lack of signal in FINRISK is likely the product of lower-quality MT-CN  
554 measurements in FINRISK, which displayed heterogeneity across survey years (**Figure S4**). This  
555 variant is located in an intergenic region between the *MYB* and *HBS1L* genes, is common across  
556 many populations, and is slightly more frequent in Finns compared to non-Finnish Europeans  
557 (gnomAD v3 MAF 34.4% vs. 26.0%). *MYB* and *HBS1L* are hematopoietic regulators<sup>69,70</sup>, and the  
558 region between them is known to be associated with many hematological parameters including fetal  
559 hemoglobin levels, hematocrit, and erythrocyte, platelet, and monocyte counts<sup>71-74</sup>. It has been  
560 suggested that these intergenic variants function by disrupting *MYB* transcription factor binding and

561 disrupting enhancer-promoter looping<sup>75</sup>. Conditioning the METSIM-only imputed array GWAS on  
562 rs9399137 – a tag SNP shown to be associated with many of these hematological parameters<sup>73</sup> –  
563 resulted in elimination of the rs9389268 signal entirely ( $P = 0.408$ ), suggesting that the haplotype  
564 responsible for the association of rs9389268 with MT-CN in our data is the same one previously  
565 known to be associated with numerous hematological phenotypes.

566 This result is not surprising considering our approach for normalizing MT-CN. Because our  
567 MT-CN estimate was based on the ratio of mtDNA coverage to nuclear DNA coverage, changes in  
568 the cell type composition of blood could result in changes in our normalized measurement if the  
569 underlying cell types have different average numbers of mitochondria. This is especially true of  
570 platelets, which can contain mitochondria but not nuclei, and whose counts are known to be  
571 associated with rs9399137.

572 rs2288464 seemed to be a good candidate due to its location in the 3' untranslated region of  
573 *MRPL34*, which codes for a large subunit protein of the mitochondrial ribosome. While the association  
574 signal at this marker was not observed in the WGS data ( $P = 0.0655$ ), based on the observed effect  
575 size of this variant in WES and imputed data as well as the number of WGS datasets available, there  
576 was insufficient power ( $\sim 0.5\%$  at  $\alpha = 5 \times 10^{-7}$ ) to robustly detect this association in the WGS data<sup>76</sup>.

577 We next performed rare variant association (RVAS) analyses using a mixed-model version of  
578 SKAT-O<sup>48</sup> to test for genes in which the presence of high-impact rare variants might be associated  
579 with MT-CN levels (see Material and Methods; **Figure 3, Table 5**). Using WES data, the only gene  
580 passing the Bonferroni-adjusted  $P$  value threshold of  $2.16 \times 10^{-6}$  was *TMBIM1* ( $P = 2.96 \times 10^{-8}$ ), a  
581 member of a gene family thought to regulate cell death pathways<sup>77</sup>. *TMBIM1* has been shown to be  
582 protective against non-alcoholic fatty liver disease (NAFLD), progression to non-alcoholic  
583 steatohepatitis, and insulin resistance in mice and macaques<sup>78</sup>. Interestingly, in our analysis - in which  
584 a burden test was determined to be optimal by SKAT-O - rare, putatively high-impact variants in



585 *TMBIM1* were associated with a higher MT-CN (**Figure 3c**). Higher MT-CN was, in turn, associated  
586 with less severe metabolic syndrome, suggesting that *TMBIM1* is actually a risk gene, not a protective  
587 one. Thus, the published function of *TMBIM1* makes it a strong candidate, although the direction of  
588 effect in our data disagreed with the direction suggested by prior work in model organisms<sup>78</sup>.

589

### 590 **Inference of causality in the association between MT-CN and insulin**

591 To further understand the association between MT-CN and fasting serum insulin, we employed a  
592 Mendelian randomization (MR) approach with MT-CN as the exposure and insulin as the outcome.  
593 Using penalized regression, we leveraged our extensive phenotype data to build a genetic instrument  
594 from a large number of genetic variants and adjust for possible confounders via a novel approach  
595 (see Material and Methods; **Figure 4**). We believe this approach to be more robust to violations of  
596 key MR assumptions than other methods in situations where limited data are available and few robust  
597 genotype-exposure associations are known. We restricted our analysis to METSIM samples due to  
598 batch effects and inconsistencies in available quantitative trait data observed across FINRISK survey  
599 years (**Figure S4**). The effect sizes of the instrument in the causality test for insulin levels are shown  
600 in **Figure 4d**. We calculated our instrument using either L1 or L2 regularization. In both cases, the  
601 MT-CN instrument was not a significant predictor ( $\alpha = 0.05$ ) of insulin when we constructed our  
602 instrument from WGS variants, but was significant when the instrument was constructed from  
603 imputed array variants. This was likely due to the larger sample size of the imputed array data set.  
604 However, the effect estimates were remarkably similar across all four cases. As a result,  
605 inverse-variance weighted meta-analysis across datasets yielded highly significant P values for both  
606 penalties. In summary, our analysis provided evidence for a significant causal role for MT-CN in  
607 determining fasting serum insulin levels that was robust to the choice of regression penalty when

608 building the genetic instrument. We note that this evidence for causality comes with some caveats  
609 (see Material and Methods).

610

### 611 **Replication and biological interpretation**

612 In principle, changes in MT-CN can be caused by changes in the number of mitochondrial genome  
613 copies within cells or by changes in the blood cell type composition. Based on the association with  
614 rs9389268 and the nuances of the normalization procedure described above, we sought to test the  
615 hypothesis that our MT-CN measurement primarily reflects the cell type composition of the blood  
616 rather than the number of mitochondria per cell. We used imputed array genotype and phenotype  
617 data from the UK Biobank (N = 357,656) for this purpose<sup>79</sup>.

618 We first tested cell counts from the UK Biobank (UKBB) against a polygenic risk score (PRS)  
619 for MT-CN built using the genetic instrument from the Finnish data. Leukocyte, neutrophil, and platelet  
620 counts were all significantly associated with MT-CN PRS conditional on age, age<sup>2</sup>, and sex (see  
621 Material and Methods, **Table 6**). However, adjusting for neutrophil counts in the leukocyte regression  
622 eliminated the signal (PRS regression coefficient P = 0.839), suggesting that the leukocyte count  
623 signal was driven by the effect of neutrophil count. We removed any high leverage, large residual  
624 samples and repeated the neutrophil and platelet count regressions to ensure that this result was  
625 robust to outliers and found no appreciable change in significance (**Table 6**). As a result, we  
626 concluded that our MT-CN measurement was significantly associated with neutrophil and platelet  
627 counts. Subsequent analyses were performed both with and without adjustment for these variables,  
628 as described below.

629 We note that the effect directions of the associations of platelet counts with metS and MT-CN  
630 PRS seem inconsistent at first glance, as platelet counts were positively correlated with MT-CN PRS  
631 (**Table 6**) and metS (**Table S3**) while MT-CN and insulin (a proxy for metS) were negatively correlated

632 **(Figure 1b)**. However, the FinMetSeq regression model in **Figure 1b** was not conditional on any  
633 other covariates (although age, age<sup>2</sup>, and sex were regressed out of the MT-CN measurement prior to  
634 this analysis), while the UKBB models that gave rise to **Table 6** and **Table S3** adjusted for many  
635 additional covariates, including 20 PCs and age-sex interaction terms. As a result, the effect  
636 directions for the analyses in the two datasets are not directly comparable.

637 We next tested for associations between MT-CN PRS and several cardiometabolic phenotypes  
638 from the test in **Figure 1a** (see Material and Methods). With the exception of C-reactive protein, which  
639 showed no significant association, all tested phenotypes showed nominal association with MT-CN  
640 PRS at  $\alpha = 0.05$ , with total triglycerides and HDL being the only traits surviving Bonferroni correction  
641 **(Table 7)**. We interpret this as replication of the link between mitochondrial genome copy number and  
642 metabolic syndrome in a large, independent data set.

643 To determine whether there was any association between MT-CN and metabolic syndrome not  
644 mediated through cell counts, we repeated the tests of cardiometabolic trait association with MT-CN  
645 PRS with adjustment for platelet and neutrophil counts. HDL was the only trait with a nominal ( $\alpha =$   
646 0.05) association with PRS under this adjustment, but this signal was not strong enough to survive  
647 Bonferroni correction **(Table 7)**. This suggests that the associations we observed between MT-CN  
648 and metabolic traits arose simply because MT-CN is a proxy for platelet and neutrophil count. This  
649 was supported by the fact that direct testing of platelets and neutrophils against triglycerides, fat  
650 mass, and HDL yielded remarkably significant associations, which survived *post-hoc* removal of  
651 high-leverage, high-residual outlier samples **(Table S3)**. This evidence for MT-CN as a proxy for  
652 platelet and neutrophil counts strongly suggests that the causal relationship observed in the  
653 Mendelian randomization experiment (see above) in fact represents a causative role for neutrophils  
654 and platelet counts in setting serum insulin levels.

655        Given the strong observed associations between blood cell count phenotypes and MT-CN  
656 PRS, we used these blood phenotypes to seek replication of the genetic associations detected in  
657 Finnish data. Using imputed UKBB genotype data, we tested the expected alternate allele dosage of  
658 both rs2288464 and rs9389268 against the same blood cell traits mentioned above, using linear  
659 regression (**Table S4**; expected alternate allele dosage was calculated from genotype call  
660 probabilities as  $DS = P(0/1) + 2P(1/1)$ ). As expected given its known associations with multiple  
661 hematological parameters (see above), rs9389268 showed strong associations with all tested blood  
662 cell phenotypes. rs2288464 was not significantly associated with any of the five phenotypes after  
663 correction for multiple testing, although a nominal association was detected with total leukocyte count.  
664 This further strengthens our belief that rs9389268 is truly associated with MT-CN through blood cell  
665 composition. We also tested *TMBIM1* against the same blood cell traits in UKBB using SKAT-O<sup>48</sup>, and  
666 found no significant associations (**Table S4**). This may mean that *TMBIM1* affects MT-CN through a  
667 mechanism other than altering blood cell type composition.

668        As further evidence that MT-CN is a proxy for blood cell composition, we looked up MT-CN  
669 association P values in METSIM for the top five neutrophil and platelet count QTLs from the  
670 NHGRI-EBI GWAS Catalog. Out of ten variants tested, five had  $P < 0.05$  in METSIM (**Table S11**). We  
671 note that three of these five were either near or identical to known MT-CN loci (including rs9389268,  
672 the marker identified in this study). rs25645, a variant reported to be highly associated with neutrophil  
673 count<sup>68</sup>, is only 2.5 kb away from rs709591, a SNP with a reported suggestive association with  
674 MT-CN<sup>27</sup> and a P value of  $1.61 \times 10^{-4}$  in our METSIM study. Moreover, rs11759553, a  
675 platelet-associated variant<sup>68</sup>, is 324 kb away from rs9389268, the lead marker for MT-CN in METSIM  
676 (rs11759553  $P = 2.15 \times 10^{-10}$  in METSIM). Finally, rs445 was reported as a lead marker for both  
677 MT-CN association<sup>25</sup> and platelet count<sup>68</sup>. rs445 has  $P = 0.048$  for association with MT-CN in  
678 METSIM. While none of the 10 known cell count-associated markers tested achieved significance

679 beyond a Bonferroni threshold, the overlap between these variants and independently-measured  
680 MT-CN QTLs was suggestive of a relationship between cell counts and whole blood-derived MT-CN.

681 Using UKBB data, we further sought to generate hypotheses for other phenotypic associations  
682 with MT-CN. To this end, we performed a phenome-wide screen of MT-CN PRS against all of the  
683 UKBB phenotypes available to us. To curate and transform these phenotypes, we used a modified  
684 version of PHEASANT<sup>61,62</sup>, which outputs all continuous variables in both raw and inverse  
685 rank-normalized form. We chose to interpret the results from the normalized continuous variables  
686 (**Table S5**) to be conservative and robust to outliers, although the results of the raw continuous  
687 variable analyses were similar (**Table S6**). No metabolic syndrome traits appeared among the tested  
688 traits with  $q < 0.05$ . However, the tests for HDL cholesterol, self-reported heart attack, and  
689 doctor-diagnosed heart attack did yield somewhat suggestive results ( $q = 0.123, 0.176, \text{ and } 0.176$ ,  
690 respectively). We also repeated this screen with adjustment for neutrophil and platelet counts (**Table**  
691 **S7** and **Table S8**), resulting again in no metabolic syndrome phenotypes achieving  $q < 0.05$ . The  
692 addition of neutrophil and platelet counts as covariates attenuated the suggestive signals for HDL  
693 cholesterol, self-reported heart attack, and doctor-diagnosed heart attack ( $q = 0.284, 0.391, \text{ and}$   
694  $0.402$ , respectively).

695

## 696 **Discussion**

697 We have described one of the most well-powered studies to date of the genetic relationship  
698 between MT-CN measurements in blood and cardiometabolic phenotypes. Our study is one of very  
699 few of which we are aware to utilize WGS data, found to be the most reliable method for estimating  
700 MT-CN in a recent study<sup>18</sup>, for this purpose. Our data show highly significant associations between  
701 blood-derived MT-CN measurements and several cardiometabolic traits, particularly insulin and fat  
702 mass. We observed strong heritability of MT-CN (31%), on par with other widely studied

703 cardiometabolic traits such as LDL, and identified one single marker association on a haplotype  
704 previously associated with several hematological parameters<sup>71–74</sup>. A previous study using qPCR to  
705 quantify MT-CN reported two sub-threshold QTLs<sup>27</sup>; of these markers, only rs709591 replicated in our  
706 study ( $P = 1.61 \times 10^{-4}$ ). We also report one gene with a rare-variant association with MT-CN, *TMBIM1*,  
707 that has a known link to non-alcoholic fatty liver disease<sup>78</sup>. More work is needed to replicate this  
708 genetic association.

709       Using a novel multiple-variant instrument-building method, we report evidence from Mendelian  
710 randomization supporting a causal role for MT-CN in metabolic syndrome. Further, we used UK  
711 Biobank data to show that not only does the link between MT-CN and metabolic syndrome replicate in  
712 an independent data set using a polygenic risk score approach. Contrary to previous claims that  
713 variability in the number of mitochondria per cell is responsible for CHD risk<sup>12</sup>, this association is  
714 mediated by neutrophil and platelet counts.

715       One important question that our study cannot definitively resolve is the relative contribution of  
716 intracellular mitochondrial abundance versus cell-type composition differences in determining the  
717 measured MT-CN value. We identified a MT-CN association result at a known QTL for cell type  
718 composition of blood<sup>71–74</sup> (*HBS1L-MYB*), and we further replicated a prior sub-threshold association at  
719 a different neutrophil-associated locus<sup>67,68</sup> (rs709591). Together, these results argue that cell type  
720 composition is an important component of this measurement. On the other hand, two other significant  
721 associations from the Finnish dataset (rs2288464, *TMBIM1*) showed no effect on cell type  
722 composition in the UK Biobank. Future work in large cohorts with both WGS and cell count data –  
723 which were not simultaneously measured in any samples in this study – will be required to rigorously  
724 determine what blood-derived MT-CN primarily measures. However, the results of our MR and UK  
725 Biobank analyses together suggest that MT-CN is causally related to metabolic syndrome traits, and  
726 that this relationship is mediated by cell-type composition differences.

727           There is prior evidence to support the role of inflammation – specifically via innate immune  
728 cells such as neutrophils – in the etiology of type 2 diabetes (T2D) and insulin resistance<sup>80–82</sup>, which  
729 suggests a plausible model by which peripheral blood neutrophil count could influence metabolic  
730 syndrome. Nutrient excess and high fat diets are known to recruit neutrophils into tissues, which then  
731 cause insulin resistance both by releasing TNF- $\alpha$  and IL-6 and by upregulating cyclooxygenase<sup>80</sup>.  
732 This leads to increased LTB4 and subsequent upregulation of NF- $\kappa$ B, a central regulator of  
733 inflammation. Moreover, free fatty acids also cause neutrophils to stay in tissues longer, resulting in  
734 persistent inflammation and leading to insulin resistance<sup>80</sup>. While it is known that inflammation, and  
735 particularly neutrophils, play a role in metabolic syndrome, our results strongly suggest that peripheral  
736 blood neutrophil count causally contributes to this process and is associated with heritable genetic  
737 variation in the human population. Overall, our work provides further insight into the role that  
738 inflammation plays in metabolic syndrome and supports the idea that targeting inflammation may be a  
739 fruitful avenue of investigation in developing future therapeutics.

740

## 741 **Supplemental Information Description**

742 Supplemental data include 8 figures and 11 tables.

743

## 744 **Acknowledgements**

745 This work was funded by the NHGRI Centers for Common Disease Genetics (grant number UM1  
746 HG008853 to I.M.H. and N.O.S), the NHGRI large-scale sequencing grant (grant number  
747 5U54HG003079), the Sigrid Jusélius Foundation (to S.R.), the University of Helsinki HiLIFE Fellow  
748 grants 2017-2020 (to S.R.), the Academy of Finland Center of Excellence in Complex Disease  
749 Genetics (grant number 312062 to S.R.), the Academy of Finland (grant number 285380 to S.R.), the

750 National Heart, Lung and Blood Institute (grant number T32HL007081 to E.Y.), and the National  
751 Center for Advancing Translational Sciences (grant number UL1TR002345 to E.Y.).

752 We thank Hyeim Jung for her help in identifying outlier individuals as well as the WashU data  
753 production team, in particular Robert Fulton, Lucinda Fulton, Catrina Fronick, Aye Wollam and Susan  
754 K. Dutcher. This research has been conducted using the UK Biobank Resource under Application  
755 Number 56546. The FINRISK samples used for the research were obtained from the FINRISK Study  
756 and from THL Biobank. We thank all study participants for their generous participation at THL  
757 Biobank and the FINRISK Study.

758

## 759 **Declaration of Interests**

760 N.O.S has received grant funding from Regeneron Pharmaceuticals for unrelated work. The rest of  
761 the authors declare no competing interests.

762

## 763 **Web Resources**

764 EPACTS, <https://genome.sph.umich.edu/wiki/EPACTS>

765 ImPerm, <https://github.com/mtorchiano/ImPerm>

766 NHGRI-EBI GWAS Catalog, <https://www.ebi.ac.uk/gwas>

767 smartPCA, <https://github.com/DReichLab/EIG>

768

## 769 **Data and Code Availability**

770 METSIM WGS, METSIM WES, and FINRISK WES sequence data are available through dbGaP  
771 (accession numbers phs001579, phs000752, and phs000756). METSIM callsets from WGS and  
772 imputed array data as well as MT-CN phenotype values will soon be available through AnVIL.



773 Imputed array GWAS summary statistics from METSIM and and WES SKAT-O summary statistics  
774 from the joint dataset are freely available at  
775 <https://wustl.box.com/s/7xfbmqx2r4kg8p8bfc7vpqlrmqvhm0lx>. Genomic and phenotypic data for the  
776 FINRISK cohort are obtainable through THL Biobank, the Finnish Institute for Health and Welfare,  
777 Finland (<https://thl.fi/en/web/thl-biobank>).

778

## 779 **References**

- 780 1. Koliaki, C., and Roden, M. (2016). Alterations of Mitochondrial Function and Insulin Sensitivity in Human  
781 Obesity and Diabetes Mellitus | Annual Review of Nutrition. *Annu. Rev. Nutr.* **36**, 337–367.
- 782 2. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. (2003). Obesity is  
783 associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* **112**, 1796–1808.
- 784 3. Kim, J.-A., Wei, Y., and Sowers, J.R. (2008). Role of Mitochondrial Dysfunction in Insulin Resistance. *Circ.*  
785 *Res.* **102**, 401–414.
- 786 4. Burgueño, A.L., Cabrerizo, R., Gonzales Mansilla, N., Sookoian, S., and Pirola, C.J. (2013). Maternal  
787 high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial  
788 DNA copy number and transcriptional activity of liver PPARGC1A. *J. Nutr. Biochem.* **24**, 6–13.
- 789 5. Sookoian, S., Rosselli, M.S., Gemma, C., Burgueño, A.L., Gianotti, T.F., Castaño, G.O., and Pirola, C.J.  
790 (2010). Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation  
791 of the peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  promoter. *Hepatology* **52**, 1992–2000.
- 792 6. Begriche, K., Igoudjil, A., Pessayre, D., and Fromenty, B. (2006). Mitochondrial dysfunction in NASH:  
793 Causes, consequences and possible means to prevent it. *Mitochondrion* **6**, 1–28.
- 794 7. Zhou, X., Li, R., Liu, X., Wang, L., Hui, P., Chan, L., Saha, P.K., and Hu, Z. (2016). ROCK1 reduces  
795 mitochondrial content and irisin production in muscle suppressing adipocyte browning and impairing insulin  
796 sensitivity. *Sci. Rep.* **6**, 29669.
- 797 8. Ren, J., Pulakat, L., Whaley-Connell, A., and Sowers, J.R. (2010). Mitochondrial biogenesis in the metabolic  
798 syndrome and cardiovascular disease. *J. Mol. Med.* **88**, 993–1001.
- 799 9. Stephenson, E.J., and Hawley, J.A. (2014). Mitochondrial function in metabolic health: A genetic and  
800 environmental tug of war. *Biochimica et Biophysica Acta (BBA) - General Subjects* **1840**, 1285–1294.
- 801 10. Szendroedi, J., Phielix, E., and Roden, M. (2012). The role of mitochondria in insulin resistance and type 2  
802 diabetes mellitus. *Nat. Rev. Endocrinol.* **8**, 92–103.
- 803 11. Ding, J., Sidore, C., Butler, T.J., Wing, M.K., Qian, Y., Meirelles, O., Busonero, F., Tsoi, L.C., Maschio, A.,  
804 Angius, A., et al. (2015). Assessing Mitochondrial DNA Variation and Copy Number in Lymphocytes of ~2,000  
805 Sardinians Using Tailored Sequencing Analysis Tools. *PLoS Genet.* **11**, e1005306.

- 806 12. Chen, S., Xie, X., Wang, Y., Gao, Y., Xie, X., Yang, J., and Ye, J. (2014). Association between leukocyte  
807 mitochondrial DNA content and risk of coronary heart disease: A case-control study. *Atherosclerosis* 237,  
808 220–226.
- 809 13. Lee, H.K., Song, J.H., Shin, C.S., Park, D.J., Park, K.S., Lee, K.U., and Koh, C.-S. (1998). Decreased  
810 mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes  
811 mellitus. *Diabetes Res. Clin. Pract.* 42, 161–167.
- 812 14. Shoar, Z., Goldenthal, M.J., De Luca, F., and Suarez, E. (2016). Mitochondrial DNA content and function,  
813 childhood obesity, and insulin resistance. *Endocr. Res.* 41, 49–56.
- 814 15. Song, J., Oh, J.Y., Sung, Y.-A., Pak, Y.K., Park, K.S., and Lee, H.K. (2001). Peripheral Blood Mitochondrial  
815 DNA Content Is Related to Insulin Sensitivity in Offspring of Type 2 Diabetic Patients. *Diabetes Care* 24,  
816 865–869.
- 817 16. Weng, S.-W., Lin, T.-K., Liou, C.-W., Chen, S.-D., Wei, Y.-H., Lee, H.-C., Chen, I.-Y., Hsieh, C.-J., and  
818 Wang, P.-W. (2009). Peripheral blood mitochondrial DNA content and dysregulation of glucose metabolism.  
819 *Diabetes Res. Clin. Pract.* 83, 94–99.
- 820 17. Liu, L.-P., Cheng, K., Ning, M.-A., Li, H.-H., Wang, H.-C., Li, F., Chen, S.-Y., Qu, F.-L., and Guo, W.-Y.  
821 (2017). Association between peripheral blood cells mitochondrial DNA content and severity of coronary heart  
822 disease. *Atherosclerosis* 261, 105–110.
- 823 18. Longchamps, R.J., Castellani, C.A., Yang, S.Y., Newcomb, C.E., Sumpter, J.A., Lane, J., Grove, M.L.,  
824 Guallar, E., Pankratz, N., Taylor, K.D., et al. (2020). Evaluation of mitochondrial DNA copy number estimation  
825 techniques. *PLoS One* 15, e0228166.
- 826 19. Guyatt, A.L., Burrows, K., Guthrie, P.A.I., Ring, S., McArdle, W., Day, I.N.M., Ascione, R., Lawlor, D.A.,  
827 Gaunt, T.R., and Rodriguez, S. (2018). Cardiometabolic phenotypes and mitochondrial DNA copy number in  
828 two cohorts of UK women. *Mitochondrion* 39, 9–19.
- 829 20. Ashar, F.N., Zhang, Y., Longchamps, R.J., Lane, J., Moes, A., Grove, M.L., Mychaleckyj, J.C., Taylor, K.D.,  
830 Coresh, J., Rotter, J.I., et al. (2017). Association of Mitochondrial DNA Copy Number With Cardiovascular  
831 Disease. *JAMA Cardiol* 2, 1247–1255.
- 832 21. Robin, E.D., and Wong, R. (1988). Mitochondrial DNA molecules and virtual number of mitochondria per  
833 cell in mammalian cells. *J. Cell. Physiol.* 136, 507–513.
- 834 22. Maianski, N.A., Geissler, J., Srinivasula, S.M., Alnemri, E.S., Roos, D., and Kuijpers, T.W. (2004).  
835 Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. *Cell Death Differ.* 11,  
836 143–153.
- 837 23. Zharikov, S., and Shiva, S. (2013). Platelet mitochondrial function: from regulation of thrombosis to  
838 biomarker of disease. *Biochem. Soc. Trans.* 41, 118–123.
- 839 24. Cai, N., Chang, S., Li, Y., Li, Q., Hu, J., Liang, J., Song, L., Kretzschmar, W., Gan, X., Nicod, J., et al.  
840 (2015). Molecular signatures of major depression. *Curr. Biol.* 25, 1146–1156.
- 841 25. Cai, N., Li, Y., Chang, S., Liang, J., Lin, C., Zhang, X., Liang, L., Hu, J., Chan, W., Kendler, K.S., et al.  
842 (2015). Genetic Control over mtDNA and Its Relationship to Major Depressive Disorder. *Curr. Biol.* 25,  
843 3170–3177.
- 844 26. Curran, J.E., Johnson, M.P., Dyer, T.D., Göring, H.H.H., Kent, J.W., Charlesworth, J.C., Borg, A.J., Jowett,  
845 J.B.M., Cole, S.A., MacCluer, J.W., et al. (2007). Genetic determinants of mitochondrial content. *Hum. Mol.*

846 Genet. 16, 1504–1514.

847 27. Guyatt, A.L., Brennan, R.R., Burrows, K., Guthrie, P.A.I., Ascione, R., Ring, S.M., Gaunt, T.R., Pyle, A.,  
848 Cordell, H.J., Lawlor, D.A., et al. (2019). A genome-wide association study of mitochondrial DNA copy number  
849 in two population-based cohorts. *Hum. Genomics* 13, 6.

850 28. Pajukanta, P., Terwilliger, J.D., Perola, M., Hiekkalinna, T., Nuotio, I., Ellonen, P., Parkkonen, M., Hartiala,  
851 J., Ylitalo, K., Pihlajamäki, J., et al. (1999). Genomewide scan for familial combined hyperlipidemia genes in  
852 finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B  
853 levels. *Am. J. Hum. Genet.* 64, 1453–1463.

854 29. Pajukanta, P., Allayee, H., Krass, K.L., Kuraishy, A., Soro, A., Lilja, H.E., Mar, R., Taskinen, M.-R., Nuotio,  
855 I., Laakso, M., et al. (2003). Combined analysis of genome scans of dutch and finnish families reveals a  
856 susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. *Am. J. Hum. Genet.* 72,  
857 903–917.

858 30. Laakso, M., Kuusisto, J., Stančáková, A., Kuulasmaa, T., Pajukanta, P., Lusa, A.J., Collins, F.S., Mohlke,  
859 K.L., and Boehnke, M. (2017). The Metabolic Syndrome in Men study: a resource for studies of metabolic and  
860 cardiovascular diseases. *J. Lipid Res.* 58, 481–493.

861 31. Borodulin, K., Tolonen, H., Jousilahti, P., Jula, A., Juolevi, A., Koskinen, S., Kuulasmaa, K., Laatikainen, T.,  
862 Männistö, S., Peltonen, M., et al. (2018). Cohort Profile: The National FINRISK Study. *Int. J. Epidemiol.* 47,  
863 696–696i.

864 32. (2019). Picard Toolkit (Broad Institute, GitHub repository).

865 33. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R.,  
866 and 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and  
867 SAMtools. *Bioinformatics* 25, 2078–2079.

868 34. Jun, G., Flickinger, M., Hetrick, K.N., Romm, J.M., Doheny, K.F., Abecasis, G.R., Boehnke, M., and Kang,  
869 H.M. (2012). Detecting and estimating contamination of human DNA samples in sequencing and array-based  
870 genotype data. *Am. J. Hum. Genet.* 91, 839–848.

871 35. McCarthy, S., Das, S., Kretschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang, H.M., Fuchsberger,  
872 C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*  
873 *Genet.* 48, 1279–1283.

874 36. Locke, A.E., Steinberg, K.M., Chiang, C.W.K., Service, S.K., Havulinna, A.S., Stell, L., Pirinen, M., Abel,  
875 H.J., Chiang, C.C., Fulton, R.S., et al. (2019). Exome sequencing of Finnish isolates enhances rare-variant  
876 association power. *Nature* 572, 323–328.

877 37. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel,  
878 G., Rivas, M.A., Hanna, M., et al. (2011). A framework for variation discovery and genotyping using  
879 next-generation DNA sequencing data. *Nat. Genet.* 43, 491–498.

880 38. Tan, A., Abecasis, G.R., and Kang, H.M. (2015). Unified representation of genetic variants. *Bioinformatics*  
881 31, 2202–2204.

882 39. Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M., and Chen, W.-M. (2010). Robust  
883 relationship inference in genome-wide association studies. *Bioinformatics* 26, 2867–2873.

884 40. Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features.

885 *Bioinformatics* 26, 841–842.

886 41. Fromer, M., Moran, J.L., Chambert, K., Banks, E., Bergen, S.E., Ruderfer, D.M., Handsaker, R.E.,  
887 McCarroll, S.A., O'Donovan, M.C., Owen, M.J., et al. (2012). Discovery and statistical genotyping of  
888 copy-number variation from whole-exome sequencing depth. *Am. J. Hum. Genet.* 91, 597–607.

889 42. Kloss-Brandstätter, A., Pacher, D., Schönherr, S., Weissensteiner, H., Binna, R., Specht, G., and  
890 Kronenberg, F. (2011). HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial  
891 DNA haplogroups. *Hum. Mutat.* 32, 25–32.

892 43. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: a tool for genome-wide complex trait  
893 analysis. *Am. J. Hum. Genet.* 88, 76–82.

894 44. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing heritability for disease  
895 from genome-wide association studies. *Am. J. Hum. Genet.* 88, 294–305.

896 45. Yang, J., Bakshi, A., Zhu, Z., Hemani, G., Vinkhuyzen, A.A.E., Lee, S.H., Robinson, M.R., Perry, J.R.B.,  
897 Nolte, I.M., van Vliet-Ostaptchouk, J.V., et al. (2015). Genetic variance estimation with imputed variants finds  
898 negligible missing heritability for human height and body mass index. *Nat. Genet.* 47, 1114–1120.

899 46. Evans, L.M., Tahmasbi, R., Vrieze, S.I., Abecasis, G.R., Das, S., Gazal, S., Bjelland, D.W., de Candia, T.R.,  
900 Haplotype Reference Consortium, Goddard, M.E., et al. (2018). Comparison of methods that use whole  
901 genome data to estimate the heritability and genetic architecture of complex traits. *Nat. Genet.* 50, 737–745.

902 47. Balduzzi, S., Rücker, G., and Schwarzer, G. (2019). How to perform a meta-analysis with R: a practical  
903 tutorial. *Evid. Based. Ment. Health* 22, 153–160.

904 48. Lee, S., Emond, M.J., Bamshad, M.J., Barnes, K.C., Rieder, M.J., Nickerson, D.A., NHLBI GO Exome  
905 Sequencing Project—ESP Lung Project Team, Christiani, D.C., Wurfel, M.M., and Lin, X. (2012). Optimal  
906 unified approach for rare-variant association testing with application to small-sample case-control whole-exome  
907 sequencing studies. *Am. J. Hum. Genet.* 91, 224–237.

908 49. Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., and Shendure, J. (2014). A general  
909 framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* 46, 310–315.

910 50. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., and Cunningham, F.  
911 (2016). The Ensembl Variant Effect Predictor. *Genome Biol.* 17, 122.

912 51. Palmer, T.M., Lawlor, D.A., Harbord, R.M., Sheehan, N.A., Tobias, J.H., Timpson, N.J., Davey Smith, G.,  
913 and Sterne, J.A.C. (2012). Using multiple genetic variants as instrumental variables for modifiable risk factors.  
914 *Stat. Methods Med. Res.* 21, 223–242.

915 52. Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization Paths for Generalized Linear Models via  
916 Coordinate Descent. *J. Stat. Softw.* 33, 1–22.

917 53. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation  
918 PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4, 7.

919 54. Burgess, S., and Thompson, S.G. (2013). Use of allele scores as instrumental variables for Mendelian  
920 randomization. *Int. J. Epidemiol.* 42, 1134–1144.

921 55. Beasley, T.M., Erickson, S., and Allison, D.B. (2009). Rank-based inverse normal transformations are  
922 increasingly used, but are they merited? *Behav. Genet.* 39, 580–595.

- 923 56. Blom, G. (1958). Statistical estimates and transformed beta-variables. *Almqvist & Wiksell*.
- 924 57. van Buuren, S., and Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations  
925 in R. *Journal of Statistical Software, Articles 45*, 1–67.
- 926 58. Honaker, J., King, G., and Blackwell, M. (2011). Amelia II: A Program for Missing Data. *Journal of*  
927 *Statistical Software, Articles 45*, 1–47.
- 928 59. Cole, S.R., Platt, R.W., Schisterman, E.F., Chu, H., Westreich, D., Richardson, D., and Poole, C. (2010).  
929 Illustrating bias due to conditioning on a collider. *Int. J. Epidemiol.* 39, 417–420.
- 930 60. VanderWeele, T.J., Tchetgen Tchetgen, E.J., Cornelis, M., and Kraft, P. (2014). Methodological challenges  
931 in mendelian randomization. *Epidemiology 25*, 427–435.
- 932 61. Neale, B. Neale Lab UK Biobank Analysis.
- 933 62. Millard, L.A.C., Davies, N.M., Gaunt, T.R., Davey Smith, G., and Tilling, K. (2018). Software Application  
934 Profile: PHEASANT: a tool for performing automated phenome scans in UK Biobank. *Int. J. Epidemiol.* 47,  
935 29–35.
- 936 63. Storey, J.D., Bass, A.J., Dabney, A., and Robinson, D. (2019). qvalue: Q-value estimation for false  
937 discovery rate control.
- 938 64. Chen, L., Abel, H.J., Das, I., Larson, D.E., Ganel, L., Kanchi, K.L., Regier, A.A., Young, E.P., Kang, C.J.,  
939 Scott, A.J., et al. (2020). Association of Structural Variation with Cardiometabolic Traits in Finns.
- 940 65. Kaess, B., Fischer, M., Baessler, A., Stark, K., Huber, F., Kremer, W., Kalbitzer, H.R., Schunkert, H.,  
941 Riegger, G., and Hengstenberg, C. (2008). The lipoprotein subfraction profile: heritability and identification of  
942 quantitative trait loci. *J. Lipid Res.* 49, 715–723.
- 943 66. Weiss, L.A., Pan, L., Abney, M., and Ober, C. (2006). The sex-specific genetic architecture of quantitative  
944 traits in humans. *Nat. Genet.* 38, 218–222.
- 945 67. Nalls, M.A., Couper, D.J., Tanaka, T., van Rooij, F.J.A., Chen, M.-H., Smith, A.V., Toniolo, D., Zakai, N.A.,  
946 Yang, Q., Greinacher, A., et al. (2011). Multiple loci are associated with white blood cell phenotypes. *PLoS*  
947 *Genet.* 7, e1002113.
- 948 68. Chen, M.-H., Raffield, L.M., Mousas, A., Sakaue, S., Huffman, J.E., Moscati, A., Trivedi, B., Jiang, T.,  
949 Akbari, P., Vuckovic, D., et al. (2020). Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667  
950 Individuals from 5 Global Populations. *Cell* 182, 1198–1213.e14.
- 951 69. Wang, X., Angelis, N., and Thein, S.L. (2018). MYB - A regulatory factor in hematopoiesis. *Gene* 665,  
952 6–17.
- 953 70. Pandit, R.A., Svasti, S., Sripichai, O., Munkongdee, T., Triwitayakorn, K., Winichagoon, P., Fucharoen, S.,  
954 and Peerapittayamongkol, C. (2008). Association of SNP in exon 1 of HBS1L with hemoglobin F level in  
955 beta0-thalassemia/hemoglobin E. *Int. J. Hematol.* 88, 357–361.
- 956 71. Thein, S.L., Menzel, S., Peng, X., Best, S., Jiang, J., Close, J., Silver, N., Gerovasilli, A., Ping, C.,  
957 Yamaguchi, M., et al. (2007). Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait  
958 locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. *Proceedings of the National Academy*  
959 *of Sciences* 104, 11346–11351.
- 960 72. Ganesh, S.K., Zakai, N.A., van Rooij, F.J.A., Soranzo, N., Smith, A.V., Nalls, M.A., Chen, M.-H., Kottgen,

- 961 A., Glazer, N.L., Dehghan, A., et al. (2009). Multiple loci influence erythrocyte phenotypes in the CHARGE  
962 Consortium. *Nat. Genet.* *41*, 1191–1198.
- 963 73. Menzel, S., Jiang, J., Silver, N., Gallagher, J., Cunningham, J., Surdulescu, G., Lathrop, M., Farrall, M.,  
964 Spector, T.D., and Thein, S.L. (2007). The HBS1L-MYB intergenic region on chromosome 6q23.3 influences  
965 erythrocyte, platelet, and monocyte counts in humans. *Blood* *110*, 3624–3626.
- 966 74. Lin, B.D., Carnero-Montoro, E., Bell, J.T., Boomsma, D.I., de Geus, E.J., Jansen, R., Klufft, C., Mangino, M.,  
967 Penninx, B., Spector, T.D., et al. (2017). 2SNP heritability and effects of genetic variants for  
968 neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. *J. Hum. Genet.* *62*, 979–988.
- 969 75. Stadhouders, R., Aktuna, S., Thongjuea, S., Aghajani-refah, A., Pourfarzad, F., van Ijcken, W., Lenhard, B.,  
970 Rooks, H., Best, S., Menzel, S., et al. (2014). HBS1L-MYB intergenic variants modulate fetal hemoglobin via  
971 long-range MYB enhancers. *J. Clin. Invest.* *124*, 1699–1710.
- 972 76. Purcell, S., Cherny, S.S., and Sham, P.C. (2003). Genetic Power Calculator: design of linkage and  
973 association genetic mapping studies of complex traits. *Bioinformatics* *19*, 149–150.
- 974 77. Zhou, J., Zhu, T., Hu, C., Li, H., Chen, G., Xu, G., Wang, S., Zhou, J., and Ma, D. (2008). Comparative  
975 genomics and function analysis on B11 family. *Comput. Biol. Chem.* *32*, 159–162.
- 976 78. Zhao, G.-N., Zhang, P., Gong, J., Zhang, X.-J., Wang, P.-X., Yin, M., Jiang, Z., Shen, L.-J., Ji, Y.-X., Tong,  
977 J., et al. (2017). Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver  
978 disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. *Nat. Med.* *23*, 742–752.
- 979 79. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J.,  
980 Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide range of  
981 complex diseases of middle and old age. *PLoS Med.* *12*, e1001779.
- 982 80. Welty, F.K., Alfaddagh, A., and Elajami, T.K. (2016). Targeting inflammation in metabolic syndrome. *Transl.*  
983 *Res.* *167*, 257–280.
- 984 81. Creely, S.J., McTernan, P.G., Kusminski, C.M., Fisher, ff M., Da Silva, N.F., Khanolkar, M., Evans, M.,  
985 Harte, A.L., and Kumar, S. (2007). Lipopolysaccharide activates an innate immune system response in human  
986 adipose tissue in obesity and type 2 diabetes. *Am. J. Physiol. Endocrinol. Metab.* *292*, E740–E747.
- 987 82. Hotamisligil, G.S. (2017). Inflammation, metaflammation and immunometabolic disorders. *Nature* *542*,  
988 177–185.

989

## 990 **Figure Titles and Legends**

991 **Figure 1. Cardiometabolic trait associations with MT-CN in WGS data.** (A) Phenome-wide  
992 association study of normalized MT-CN against 137 cardiometabolic traits in the 4,163 sample data  
993 set. Traits are grouped into 17 categories, represented by the color of each bar. The top three most  
994 significant traits are, in order: fasting serum insulin, C-reactive protein, and fat mass. Exact P values

995 and effect estimates, as calculated by EMMAX, are listed in **Table S1**. (B) Association tests between  
996 normalized MT-CN and both fat mass and fasting serum insulin using WGS data (N = 4,163). Results  
997 are shown for the EMMAX test and a permutation test in which mitochondrial haplogroups were  
998 adjusted for.

999

1000 **Figure 2. Single-marker genetic associations with MT-CN in imputed array data.** (A) Manhattan  
1001 plot for a genome-wide association test of normalized, WES-measured MT-CN using imputed array  
1002 genotype data from METSIM (N = 9,791). Two loci markers reached the genome-wide significance of  
1003  $5 \times 10^{-8}$ , identified by lead markers rs2288464 and rs9389268. (B) Quantile-quantile (QQ) plot for the  
1004 association test shown in (A). This plot is separated by minor allele frequency bin, as indicated by the  
1005 colors and shapes of the points. (C) Boxplot showing the distributions of normalized WES-measured  
1006 MT-CN in METSIM separated by the number of rs9389268 alternate alleles as detected by imputed  
1007 array genotyping (N = 9,791). The EMMAX P value for this variant was  $1.62 \times 10^{-8}$  in imputed data.

1008

1009 **Figure 3. Gene-based associations with MT-CN in WES data.** (A) Manhattan plot and  
1010 quantile-quantile (QQ) plot for a gene-based rare variant association test of normalized,  
1011 WES-measured MT-CN using WES data from both METSIM and FINRISK (N = 19,034). The red line  
1012 represents a Bonferroni significance level of  $2.164 \times 10^{-6}$ , as 23,105 genes were included in this test.  
1013 *TMBIM1* is the only gene to reach significance at this level. (B) QQ plot for the test shown in (A). This  
1014 plot is separated by minor allele frequency bin, as indicated by the colors and shapes of the points.  
1015 (C) Boxplot showing the distributions of normalized WES-measured MT-CN, separated by the number  
1016 of WES-detected alternate alleles in *TMBIM1* with MAF < 0.01 and CADD score > 20 (N = 19,034).

1017

1018 **Figure 4. Mendelian randomization approach and results.** (A) Formulation of the Mendelian  
1019 Randomization causality test.  $G$  represents genotypes,  $Z$  is a genetic instrument value constructed  
1020 from  $G$ ,  $X$  represents  $\ln(\text{MT-CN})$ ,  $Y$  represents  $\ln(\text{Insulin})$ , and  $U$  represents any confounders of the  
1021 association between  $X$  and  $Y$ . The arrow from  $X$  to  $Y$  is dashed to indicate that although an association  
1022 is known, the relationship is not known to be causal. In this formulation, a significant association  
1023 between  $Z$  and  $Y$  would provide evidence that  $X$  is casual for  $Y$ . (B) Strategy for choosing variables to  
1024 adjust for when building  $Z$  in order to enforce MR assumptions.  $A$  represents those columns of  
1025 covariate matrix  $W$  that are associated with  $Y$  (represented by the solid line between  $A$  and  $Y$ ) and  $B$   
1026 represents those columns of matrix  $W$  that are associated with  $X$  conditional on  $A$  (represented by the  
1027 solid line between  $B$  and  $X$ ). Dashed lines represent possible, but unproven associations. The  
1028 penalized regression of  $X$  on  $G$  used to build  $Z$  is adjusted for  $A$  and  $B$  (with no penalty) in an attempt  
1029 to prevent any associations between  $Z$  and either  $A$  or  $B$  (represented by the blue  $X$ 's). While an  
1030 association between  $B$  and  $Y$  is unlikely (represented by the dashed line between  $B$  and  $Y$ ) because  $B$   
1031 is not contained in  $A$ ,  $B$  is still adjusted for in the penalized regression to be as conservative as  
1032 possible. (C) Strategy for choosing covariates to adjust for in the causality test of  $Y$  against  $Z$  in  
1033 another attempt to reduce the impact of any remaining associations between  $Z$  and  
1034 assumption-violating variables. Covariate sets I, II, III, and IV are defined by the presence of known  
1035 first-order associations (represented by black lines) with  $Z$  and  $Y$  (see Material and Methods). Yellow  
1036 lines represent relationships where a first-order association is not known, but a higher-order  
1037 association is possible. Covariate sets II, III, and IV (colored blue) are adjusted for in the causality  
1038 test because there is at least one first order association linking them to  $Z$  and  $Y$ , so they risk violating  
1039 MR assumptions 2 or 3. (D) Results of Mendelian randomization test for causality of MT-CN on  
1040 fasting serum insulin.



1041 **Tables**

1042 **Table 1. Associations of normalized MT-CN with disposition index and Matsuda ISI in METSIM.**

	Disposition index									
	Baseline					Follow-up <sup>b</sup>				
	N	$\beta$	SE	P	P <sup>*a</sup>	N	$\beta$	SE	P	P <sup>*a</sup>
<b>All subjects</b>	2975	0.094	0.004	$3.0 \times 10^{-7}$	0.0004	2492	0.062	0.004	0.002	0.068
<b>Excludes diabetic subjects at baseline</b>	2842	0.091	0.003	$1.3 \times 10^{-6}$	0.0007	2452	0.067	0.004	0.0009	0.041
<b>Excludes diabetic subjects at baseline and during follow-up</b>	2453	0.069	0.003	0.0007	0.023	2449	0.067	0.004	0.0009	0.042
	Matsuda ISI									
	Baseline					Follow-up <sup>b</sup>				
	N	$\beta$	SE	P	P <sup>*a</sup>	N	$\beta$	SE	P	P <sup>*a</sup>
<b>All subjects</b>	2975	0.192	0.005	$4.3 \times 10^{-26}$	$7.3 \times 10^{-17}$	2492	0.157	0.006	$3.7 \times 10^{-15}$	$8.7 \times 10^{-10}$
<b>Excludes diabetic subjects at baseline</b>	2842	0.191	0.005	$1.0 \times 10^{-24}$	$2.4 \times 10^{-16}$	2452	0.161	0.006	$1.3 \times 10^{-15}$	$3.0 \times 10^{-10}$
<b>Excludes diabetic subjects at baseline and during follow-up</b>	2453	0.173	0.005	$7.2 \times 10^{-18}$	$5.3 \times 10^{-12}$	2449	0.16	0.006	$1.7 \times 10^{-15}$	$3.8 \times 10^{-10}$

1043 Testing was done by linear regression using disposition and Matsuda ISI, respectively, as the dependent variable.

1044 <sup>a</sup>P\* columns represent the P value from linear regression with additional adjustment for fat mass.

1045 <sup>b</sup>Follow-up measurements were taken at a later time point.

1046

1047

1048 **Table 2. GREML heritability estimates in each cohort separately and in joint analysis.**

		WGS-measured MT-CN			WES-measured MT-CN		
		N <sup>a</sup>	h <sup>2</sup>	SE	N <sup>a</sup>	h <sup>2</sup>	SE
Joint Analysis	WGS genotypes	4149	0.17	0.06	3916	0.11	0.06
	Imputed genotypes	3916	0.16	0.06	17718	0.09	0.02
METSIM	WGS genotypes	3065	0.31	0.07	2974	0.20	0.08
	Imputed genotypes	2974	0.27	0.08	9791	0.11	0.03
FINRISK	WGS genotypes	1084	0.20	0.22	942	0.24	0.27
	Imputed genotypes	942	0.35	0.27	7927	0.08	0.03

1049 <sup>a</sup>All analyses in this table were limited to sample sets with available imputed genotype data, yielding slightly lower sample  
 1050 sizes than in other tables.

1051

1052 **Table 3. GREML and GREML-LDMS heritability estimates for normalized MT-CN and**  
 1053 **low-density lipoprotein (LDL).**

Trait	Genotype source (phenotype source)	N <sup>a</sup>	GREML		GREML-LDMS <sup>b</sup>	
			h <sup>2</sup>	SE	h <sup>2</sup>	SE
Normalized MT-CN	WGS (WGS-measured MT-CN)	3065	0.31	0.07	0.31	0.09
	Imputed array <sup>c</sup> (WES-measured MT-CN)	6789	0.11	0.04	0.14	0.05
LDL	WGS	3062	0.34	0.08	0.38	0.10
	Imputed array <sup>c</sup>	6787	0.25	0.04	0.32	0.05

1054 <sup>a</sup>All analyses are limited to METSIM data

1055 <sup>b</sup>GREML-LDMS heritability estimates are calculated using PCs 1-10 as fixed-effect covariates.

1056 <sup>c</sup>Analyses of imputed array data exclude samples with WGS data

1057 **Table 4. Single marker association results for rs2288464 and rs9389268**

		FINRISK <sup>a</sup>				METSIM				Joint Analysis			
		N	MAF	P <sup>b</sup>	Beta	N	MAF	P <sup>b</sup>	Beta	N	MAF	P <sup>b</sup>	Beta
rs2288464	Imputed	7927	0.148	0.613	0.0113	9791	0.165	<i>2.55×10<sup>-9</sup></i>	0.119	17718	0.158	<i>9.77×10<sup>-7</sup></i>	0.075
	WES	9221	0.150	0.376	0.0186	9813	0.166	<i>6.75×10<sup>-9</sup></i>	0.118	19034	0.158	<i>9.34×10<sup>-7</sup></i>	0.0734
	WGS	1084	0.142	0.383	0.0532	3065	0.161	0.113	0.0561	4149	0.156	0.0655	0.0562
rs9389268	Imputed	7927	0.354	0.189	0.0216	9791	0.347	<i>1.26×10<sup>-10</sup></i>	0.0973	17718	0.35	<i>1.62×10<sup>-8</sup></i>	0.0634
	WGS	1084	0.351	0.788	0.0121	3065	0.347	<i>3.24×10<sup>-8</sup></i>	0.150	4149	0.348	<i>7.87×10<sup>-7</sup></i>	0.115

1058 <sup>a</sup>Analyses of imputed FINRISK array data were performed with covariates for FINRISK genotyping batch.

1059 <sup>b</sup>Italicized results are significant at the appropriate threshold for the given test (see Material and Methods).

1060

1061 **Table 5. Gene-based rare variant association results for *TMBIM1***

	FINRISK			METSIM			Joint Analysis		
	N	Fraction with rare allele	P	N	Fraction with rare allele	P <sup>a</sup>	N	Fraction with rare allele	P <sup>a</sup>
WES	9221	0.016	<i>1.57×10<sup>-3</sup></i>	9813	0.013	<i>1.44×10<sup>-6</sup></i>	19034	0.014	<i>2.96×10<sup>-8</sup></i>
WGS	1084	0.028	0.489	3065	0.014	0.01	4149	0.013	0.01

1062 *TMBIM1* was the only genome-wide significant gene in the WES rare-variant association tests of METSIM and the whole  
1063 dataset.

1064 <sup>a</sup>Italicized results are significant at the appropriate threshold for the given test (see Material and Methods).

1065

1066

1067 **Table 6. Association results between blood cell count traits and MT-CN polygenic risk score in**  
 1068 **357,656 UK Biobank samples.**

Cell Type	All samples			No <i>post hoc</i> high leverage outliers		
	$\beta^a$	SE	$P^b$	$\beta^a$	SE	$P^b$
Leukocyte	-0.00856	0.00170	<i>4.42×10<sup>-7</sup></i>	-	-	-
Monocyte	-0.00119	0.00170	0.482	-	-	-
Lymphocyte	-0.00250	0.00170	0.142	-	-	-
Neutrophil	-0.00954	0.00169	<i>1.80×10<sup>-8</sup></i>	-0.00948	0.00169	<i>2.17×10<sup>-8</sup></i>
Platelet	0.00548	0.00170	<i>1.24×10<sup>-3</sup></i>	0.00548	0.00170	<i>1.25×10<sup>-3</sup></i>

1069 <sup>a</sup> $\beta$  refers to the regression coefficient of MT-CN in a linear regression of cell type onto MT-CN PRS and other covariates  
 1070 (see Material and Methods)

1071 <sup>b</sup> $P$  values below a nominal  $\alpha = 0.05$  are shown in italics

1072

1073 **Table 7. Association results between metabolic syndrome traits and MT-CN polygenic risk**  
 1074 **score in 357,656 UK Biobank samples.**

Trait	Without platelet and neutrophil adjustment			With platelet and neutrophil adjustment		
	$\beta^b$	SE	$P^c$	$\beta^b$	SE	$P^c$
Type 2 Diabetes	-0.1681	0.0826	<i>0.0419</i>	-0.1467	0.0844	0.0823
BMI	-0.0372	0.0175	<i>0.0331</i>	-0.0233	0.0175	0.1836
Fat Mass	-0.0452	0.0176	<i>0.0100</i>	-0.0318	0.0177	0.0716
C-Reactive Protein	-0.0015	0.0178	0.9305	0.0206	0.0171	0.2291
HDL	0.0573	0.0187	<i>0.0021</i>	0.0416	0.0187	<i>0.0262</i>
Total Triglycerides	-0.0500	0.0176	<i>0.0046</i>	-0.0330	0.0175	0.0603
Weight <sup>a</sup>	-0.0359	0.0176	<i>0.0414</i>	-0.0218	0.0178	0.2189

1075 <sup>a</sup>The weight phenotype tested was that which was measured at the time of impedance measurement.

1076 <sup>b</sup> $\beta$  refers to the regression coefficient of MT-CN in a linear regression of cell type onto MT-CN PRS and other covariates  
 1077 (see Material and Methods)


1078 <sup>c</sup> $P$  values below a nominal  $\alpha = 0.05$  are shown in italics

# Figure 1

It is made available under a [CC BY-NC-ND 4.0 International license](#).

**A**

Trait associations with direct MT-CN measurement




**B**


Trait	EMMAX model		Conditional on mitochondrial haplogroup	
	P	Beta	P	Beta
Fat mass	$4.48 \times 10^{-16}$	-0.137	$< 2 \times 10^{-16}$	-0.171
ln(Fasting insulin)	$2.02 \times 10^{-21}$	-0.182	$< 2 \times 10^{-16}$	-0.226

# Figure 2

Single marker test of MT-CN in imputed genotyping array data from METSIM





Single marker test of MT-CN in imputed genotyping array data from METSIM






Effect of alternate rs9389268 alleles on MT-CN




**C**



# Figure 3



# Figure 4



**D**

Dataset	N	Penalty	Beta	SE	P
WGS	3034	L1	-0.021	0.0131	0.1087
		L2	-0.0212	0.0115	0.0645
Imputed Array	6774	L1	-0.0194	0.0083	0.0192
		L2	-0.0231	0.0079	0.0037
Meta-analysis	-	L1	-0.0199	0.007	0.0045
		L2	-0.0225	0.0065	0.0006